0001821586-22-000009 | 10-Q | XBRL Viewer | Moonlake Immunotherapeutics

Of which: net loss attributable to controlling interests shareholders

(14,741,648)

(6,288,056)

^[1]

(48,038,121)

(39,325,510)

^[1],[2]

(10,110,452)

(6,288,056)

^[1]

(32,865,429)

(39,325,510)

^[1]

Of which: net loss attributable to noncontrolling interests shareholders

(4,631,196)

^[1]

(15,172,692)

^[1]

Net unrealized gain on marketable securities and short term investments

77,006

^[1]

77,006

^[1]

Foreign currency Translation

^[1]

567

^[1]

Actuarial income (loss) on employee benefit plans

89,586

1,000

^[1]

456,883

^[1]

Comprehensive loss attributable to controlling interests shareholders

166,592

1,000

^[1]

534,456

^[1]

Comprehensive loss

(14,575,056)

(6,287,056)

^[1]

(47,503,665)

(39,325,510)

^[1]

(9,998,892)

(6,287,056)

^[1]

(32,507,526)

(39,325,510)

^[1]

Comprehensive loss attributable to noncontrolling interests

$ (4,576,164)

$ 0

^[1]

$ (14,996,139)

$ 0

^[1]

Weighted-average number of shares, basic (in shares)

36,925,639

2,390,587

25,830,560

9,689,627

Weighted-average number of shares, diluted (in shares)

36,925,639

2,390,587

25,830,560

9,689,627

Basic net loss per share attributable to controlling interest shareholders (USD per share)

$ (0.27)

$ (2.63)

$ (1.27)

$ (4.06)

Diluted net loss per share attributable to controlling interest shareholders (USD per share)

$ (0.27)

$ (2.63)

$ (1.27)

$ (4.06)

Weighted-average number of shares, basic (in shares)

Operating expenses

^[3]

36,925,639

^[1]

25,830,560

^[1]

Weighted-average number of shares, diluted (in shares)

^[3]

36,925,639

^[1]

25,830,560

^[1]

Basic net loss per share attributable to controlling interest shareholders (USD per share)

$ (0.27)

$ 0

^[1]

$ (1.27)

$ 0

^[1]

Diluted net loss per share attributable to controlling interest shareholders (USD per share)

$ (0.27)

$ 0

^[1]

$ (1.27)

$ 0

^[1]

MoonLake AG Common Shares

Operating expenses

Weighted-average number of shares, basic (in shares)

^[3]

2,390,587

^[1]

9,689,627

^[1]

Weighted-average number of shares, diluted (in shares)

^[3]

2,390,587

^[1]

9,689,627

^[1]

Basic net loss per share attributable to controlling interest shareholders (USD per share)

$ 0

$ (2.63)

^[1]

$ 0

$ (4.06)

^[1]

Diluted net loss per share attributable to controlling interest shareholders (USD per share)

$ 0

$ (2.63)

^[1]

$ 0

$ (4.06)

^[1]

[1]	1 For additional details, refer to Note 3 - Basis of Presentation and Significant Accounting Policies - Restatement of Consolidated Financial Statements as of and for the Three and Nine-months Ended September 30, 2021.
[2]	3 For additional details, refer to Note 3 - Basis of Presentation and Significant Accounting Policies - Restatement of Consolidated Financial Statements as of and for the Three and Nine-months Ended September 30, 2021.
[3]	2 As a result of the Business Combination, the Company has retroactively restated the weighted average number of shares outstanding prior to April 5, 2022 to give effect to the Exchange Ratio.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT) - USD ($)

Total

Class A Ordinary Shares

Class C Ordinary Shares

Previously Reported

Revision of Prior Period, Adjustment

Total Shareholders' Equity (Deficit)

Previously Reported

Total Shareholders' Equity (Deficit)

Revision of Prior Period, Adjustment

MoonLake AG Series A Preferred Shares

Previously Reported

MoonLake AG Series A Preferred Shares

Revision of Prior Period, Adjustment

MoonLake AG Common Shares

Class A Ordinary Shares

MoonLake AG Common Shares

Class C Ordinary Shares

MoonLake AG Common Shares

Previously Reported

MoonLake AG Common Shares

Revision of Prior Period, Adjustment

MoonLake AG Common Shares Held In Treasury

Previously Reported

MoonLake AG Common Shares Held In Treasury

Revision of Prior Period, Adjustment

Additional Paid-In Capital

Previously Reported

Accumulated Deficit

Previously Reported

Accumulated Other Comprehensive Income (Loss)

Previously Reported

Noncontrolling Interests

Common stock, beginning balance (in shares) at Mar. 10, 2021

33,638,698

1,000,000

32,638,698

Equity, beginning balance at Mar. 10, 2021

$ 106,508

$ 0

$ 106,508

$ 0

$ 106,508

$ 0

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Preferred stock, ending balance (in shares) at Mar. 31, 2021

(351,673)

Common stock, ending balance (in shares) at Mar. 31, 2021

33,638,698

Equity, end balance at Mar. 31, 2021

(245,165)

$ 0

$ 106,508

$ 0

(351,673)

$ 0

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Share-based compensation expense through transfer of existing Common shares (3,330,231) to Merck KGaA, Darmstadt, Germany, and conversion of transferred shares into Series A Preferred shares (in shares)

(32,685,779)

3,330,231

(3,330,231)

Share-based compensation expense through transfer of existing Common Shares (3,330,231) to Merck KGaA, Darmstadt, Germany, and conversion of transferred shares into Series A Preferred Shares

4,851,000

$ 10,544

$ (10,544)

4,851,000

Share-based compensation granted under the equity incentive plan ESPP, and reverse vesting of Restricted Founder Shares

1,250,365

Conversion and transfer of shares between classes (in shares)

19,207,697

(19,207,697)

Conversion and transfer of shares between classes

27,659,237

$ 60,816

$ (60,816)

27,659,237

Preferred stock, ending balance (in shares) at Jun. 30, 2021

(1,000)

22,537,928

Common stock, ending balance (in shares) at Jun. 30, 2021

11,100,770

Equity, end balance at Jun. 30, 2021

828,658

$ 71,360

$ 35,148

33,760,602

(33,037,452)

(1,000)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Share-based compensation granted under the equity incentive plan ESPP, and reverse vesting of Restricted Founder Shares

(6,288,056)

^[1]

(6,288,056)

1,859,108

$ 3,281

1,855,827

1,000

^[1]

1,000

Preferred Shares purchased by a director following his appointment as chairman of the board of directors (net of share issuance cost of $4951)

342,980

495,050

$ 1,106

493,944

Share-based compensation granted under the equity incentive plan ESPP, and reverse vesting of Restricted Founder Shares (in shares)

1,026,956

Preferred stock, ending balance (in shares) at Sep. 30, 2021

22,880,908

Common stock, ending balance (in shares) at Sep. 30, 2021

12,127,726

Equity, end balance at Sep. 30, 2021

(3,104,240)

$ 72,466

$ 38,429

36,110,373

(39,325,508)

Preferred stock, beginning balance (in shares) at Dec. 31, 2021

22,880,908

680,196

22,200,712

Common stock, beginning balance (in shares) at Dec. 31, 2021

12,161,331

361,528

11,799,803

Held in Treasury, beginning balance (in shares) at Dec. 31, 2021

(1,942,837)

(57,756)

(1,885,081)

Equity, beginning balance at Dec. 31, 2021

(11,645,007)

$ 72,466

$ 38,537

$ (6,202)

42,061,984

$ 42,061,984

(53,643,615)

$ (53,643,615)

(168,177)

$ (168,177)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Share-based compensation granted under the equity incentive plan ESPP, and reverse vesting of Restricted Founder Shares

(15,880,142)

1,992,662

$ 3,791

1,988,871

Share-based compensation granted under the equity incentive plan ESPP, and reverse vesting of Restricted Founder Shares (in shares)

266,269

1,177,354

Preferred stock, ending balance (in shares) at Mar. 31, 2022

22,880,908

Common stock, ending balance (in shares) at Mar. 31, 2022

12,161,331

Held in Treasury, ending balance (in shares) at Mar. 31, 2022

(765,483)

Equity, end balance at Mar. 31, 2022

(25,266,218)

$ 72,466

$ 38,537

$ 0

$ (2,411)

44,050,855

(69,523,757)

98,092

$ 0

Preferred stock, beginning balance (in shares) at Dec. 31, 2021

22,880,908

680,196

22,200,712

Common stock, beginning balance (in shares) at Dec. 31, 2021

12,161,331

361,528

11,799,803

Held in Treasury, beginning balance (in shares) at Dec. 31, 2021

(1,942,837)

(57,756)

(1,885,081)

Equity, beginning balance at Dec. 31, 2021

(11,645,007)

$ (11,645,007)

$ 0

(11,645,007)

$ (11,645,007)

$ 0

$ 72,466

$ 38,537

$ (6,202)

42,061,984

$ 42,061,984

(53,643,615)

$ (53,643,615)

(168,177)

$ (168,177)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Conversion and transfer of shares between classes (in shares)

(48,038,121)

15,775,472

Preferred stock, ending balance (in shares) at Sep. 30, 2022

534,456

Common stock, ending balance (in shares) at Sep. 30, 2022

36,925,639

15,775,472

36,925,639

15,775,472

Held in Treasury, ending balance (in shares) at Sep. 30, 2022

Equity, end balance at Sep. 30, 2022

82,568,156

$ 0

$ 3,693

$ 1,578

$ 0

Preferred stock, beginning balance (in shares) at Mar. 31, 2022

22,880,908

Common stock, beginning balance (in shares) at Mar. 31, 2022

12,161,331

Held in Treasury, beginning balance (in shares) at Mar. 31, 2022

(765,483)

Equity, beginning balance at Mar. 31, 2022

(25,266,218)

$ 72,466

$ 38,537

$ 0

$ (2,411)

44,050,855

(69,523,757)

98,092

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Share-based compensation granted under the equity incentive plan ESPP, and reverse vesting of Restricted Founder Shares

(17,416,329)

(12,120,719)

(5,295,610)

2,484,223

1,701,614

782,609

Conversion and transfer of shares between classes (in shares)

(22,880,908)

(12,161,331)

18,501,284

15,775,472

765,483

Conversion and transfer of shares between classes

1,578

$ (48,527)

$ (25,807)

$ 1,850

$ 1,578

$ 1,614

70,870

Noncontrolling interests recognized on historical net assets of MoonLake AG in connection with the Business Combination

101,597

68,035

33,562

$ 0

8,346,506

$ (23,939)

$ (12,730)

$ 797

(14,551,870)

22,966,652

(32,404)

(8,346,506)

Issuance of Class A ordinary shares upon business combination (in shares)

18,424,355

Issuance of Class A Ordinary Shares upon Business Combination

$ 134,653,201

90,783,932

$ 1,843

90,782,089

43,869,269

Preferred stock, ending balance (in shares) at Jun. 30, 2022

Common stock, ending balance (in shares) at Jun. 30, 2022

36,925,639

15,775,472

Held in Treasury, ending balance (in shares) at Jun. 30, 2022

Equity, end balance at Jun. 30, 2022

$ 94,558,052

63,514,728

$ 0

$ 3,693

$ 1,578

$ 0

122,053,558

(58,677,824)

133,723

31,043,324

Increase (Decrease) in Stockholders' Equity [Roll Forward]

36,925,639

Issuance of Class A ordinary shares upon business combination (in shares)

11,700,000

15,775,472

18,501,284

Common stock, ending balance (in shares) at Apr. 05, 2022

52,701,111

Common stock, beginning balance (in shares) at Jun. 30, 2022

36,925,639

15,775,472

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Share-based compensation granted under the equity incentive plan ESPP, and reverse vesting of Restricted Founder Shares

$ (14,741,648)

(10,110,452)

$ (10,110,452)

(4,631,196)

2,585,160

1,772,338

$ 1,772,338

812,822

Preferred stock, ending balance (in shares) at Sep. 30, 2022

166,592

$ 111,560

$ 55,032

Common stock, ending balance (in shares) at Sep. 30, 2022

36,925,639

15,775,472

36,925,639

15,775,472

Held in Treasury, ending balance (in shares) at Sep. 30, 2022

Equity, end balance at Sep. 30, 2022

$ 82,568,156

$ 0

$ 3,693

$ 1,578

$ 0

[1]	1 For additional details, refer to Note 3 - Basis of Presentation and Significant Accounting Policies - Restatement of Consolidated Financial Statements as of and for the Three and Nine-months Ended September 30, 2021.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT) (Parenthetical) - MoonLake AG Series A Preferred Shares - USD ($)	3 Months Ended
	Sep. 30, 2021	Jun. 30, 2021
Share-based compensation expense through transfer of existing Common shares (3,330,231) to Merck KGaA, Darmstadt, Germany, and conversion of transferred shares into Series A Preferred shares (in shares)		3,330,231
Conversion and transfer of shares between classes (in shares)		19,207,697
Issuance costs	$ 4,951	$ 279,364

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)

9 Months Ended

Sep. 30, 2022

Sep. 30, 2021

^[2]

Cash flow from operating activities

Adjustments to reconcile net loss to net cash used in operating activities:

$ (48,038,121)

$ (39,325,510)

^[1]

Depreciation

9,069

2,484

Share-based payment

7,058,255

3,106,192

Share-based compensation for the in-licensing agreement

4,851,000

Net periodic pension benefit cost for the qualified pension plan

227,691

150,000

Other non-cash items

(5,504)

10,270

Changes in operating assets and liabilities:

Other receivables

(451,762)

(66,810)

Prepaid expenses

(3,030,098)

(43,645)

Trade and other payables

(513,037)

762,550

Accrued expenses and other current liabilities

445,589

2,830,291

Net cash flow used in operating activities

(44,297,918)

(27,723,178)

Cash flow from investing activities

Purchase of Short-term marketable debt securities

(42,226,022)

Purchase of property and equipment

(16,008)

(32,332)

Net cash flow used in investing activities

(42,242,030)

(32,332)

Cash flow from financing activities

Issuance of shares at incorporation

106,508

Issuance of Series A Preferred Shares, net

28,154,287

Proceeds from Business Combination

134,646,009

Contribution for Par Value of Class V Shares

42,935

Repayment of Loan Liability

(15,000,000)

Grants of additional Shares under ESPP

3,281

Net cash flow provided by financing activities

119,688,944

28,264,076

Effect of movements in exchange rates on cash held

16,826

(1,005)

Net change in cash and cash equivalents

33,165,822

507,561

Cash and cash equivalents, beginning of period

8,038,845

Cash and cash equivalents, end of period

$ 41,204,667

$ 507,561

[1]	1 For additional details, refer to Note 3 - Basis of Presentation and Significant Accounting Policies - Restatement of Consolidated Financial Statements as of and for the Three and Nine-months Ended September 30, 2021.
[2]	3 For additional details, refer to Note 3 - Basis of Presentation and Significant Accounting Policies - Restatement of Consolidated Financial Statements as of and for the Three and Nine-months Ended September 30, 2021.

Overview of the Company	9 Months Ended
Overview of the Company	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Overview of the Company	Overview of the Company Corporate Information MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. MoonLake Immunotherapeutics focuses on developing its novel tri-specific Nanobody® Sonelokimab (“SLK”), an IL-17A and IL-17F inhibitor, in multiple inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F. Unless the context otherwise requires, “MoonLake,” and the “Company” refer to the combined company following the Business Combination (as defined in Note 2 - Business Combination Agreement with Helix and Recapitalization), together with its subsidiaries.

Business Combination Agreement with Helix and Recapitalization

9 Months Ended

Sep. 30, 2022

Reverse Recapitalization [Abstract]

Business Combination Agreement with Helix and Recapitalization

On April 5, 2022 (the “Closing Date”), MoonLake Immunotherapeutics, a Cayman Islands exempted company (formerly known as Helix Acquisition Corp.) (prior to the Closing Date, “Helix” and after the Closing Date, “MoonLake” or the “Company”) consummated the previously announced business combination (the “Closing”) pursuant to that certain Business Combination Agreement dated October 4, 2021 (the “Business Combination Agreement”), by and among Helix, MoonLake Immunotherapeutics AG, a Swiss stock corporation (Aktiengesellschaft) registered with the commercial register of the Canton of Zug, Switzerland under the number CHE-433.093.536 (“MoonLake AG”), the existing equity holders of MoonLake AG set forth on the signature pages to the Business Combination Agreement and the equityholders of MoonLake AG that executed joinders to the Business Combination Agreement (collectively, the “ML Parties”), Helix Holdings LLC, a Cayman Islands limited liability company and the sponsor of Helix (the “Sponsor”), and the representative of the ML Parties (such transactions contemplated by the Business Combination Agreement collectively, the “Business Combination”). Net proceeds from the Business Combination totaled $134.7 million, which included funds held in Helix’s trust account and the completion of a concurrent PIPE investment.

Pursuant to the Business Combination Agreement, approved by the boards of directors of each of MoonLake AG and Helix, (i) the Company changed its name from Helix Acquisition Corp. to MoonLake Immunotherapeutics, and (ii) MoonLake AG merged with and into MoonLake, with MoonLake AG as the surviving company in the Business Combination and, after giving effect to such Business Combination, MoonLake AG as a subsidiary of MoonLake.

The Business Combination Agreement provided for, among other things, the following transactions:

i.Two business days prior to the Closing Date, the ML Parties and MoonLake AG effectuated a restructuring of MoonLake AG’s share capital to, among other things, (x) convert the existing Series A preferred shares of MoonLake AG, par value of CHF 0.10 per share, into an equal number of MoonLake AG Common Shares such that the ML Parties held a single class of capital share of MoonLake AG immediately prior to the Closing and (y) approve a capital increase for the issuance of 4,006,736 Class V Voting Shares of MoonLake AG, par value CHF 0.01 per share, to Helix, each Class V Voting Share due to its lower par value having ten times the voting power of a MoonLake AG Common Share (the “Restructuring”).

ii.At the Closing, 2,875,000 Class B ordinary shares of Helix, par value $0.0001 per share (the “Class B Ordinary Shares”), constituting all of the then-outstanding Class B Ordinary Shares, were automatically converted into Class A Ordinary Shares on a one-for-one basis.

iii.At the Closing, Helix amended and restated its existing memorandum and articles of association to, among other things, establish a share structure consisting of the Class A Ordinary Shares, which carry economic and voting rights, and Class C Ordinary Shares, which carry voting rights but no economic rights.

iv.On the Closing Date, Helix paid all unpaid transaction expenses and contributed $134.7 million to MoonLake AG, including $15.0 million loan repayment pursuant to a convertible loan agreement dated March 20, 2022, by and between MoonLake AG and Cormorant Asset Management LP (“Cormorant”), and assigned by Cormorant to Helix on March 31, 2022.

v.On the Closing Date, following the Restructuring, Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., and Biotechnology Value Trading Fund OS, L.P. (collectively, the “BVF Shareholders”) assigned all of their MoonLake AG Common Shares to Helix and Helix issued to the BVF Shareholders 18,501,284 Class A Ordinary Shares.

vi.On the Closing Date, following the Restructuring, Helix issued 15,775,472 Class C Ordinary Shares to the ML Parties (other than the BVF Shareholders). Please refer to Note 11 - Shareholders’ Equity (Deficit) for additional details on the exchange mechanism adopted.

Additionally, on the Closing Date, Helix issued to the PIPE Investors (as defined below in the section entitled “PIPE Financing”) an aggregate of 11,700,000 Class A Ordinary Shares.

As of the open of trading on April 6, 2022, the Class A Ordinary Shares, formerly those of Helix, began trading on The Nasdaq Capital Market (“Nasdaq”) under the trading symbol “MLTX.”

PIPE Financing

On October 4, 2021, concurrently with the execution of the Business Combination Agreement, and subsequently on March 31, 2022 and April 4, 2022, Helix entered into subscription agreements with certain investors (collectively, the “PIPE Investors,” which includes affiliates of the Sponsor and certain existing equityholders of MoonLake AG) pursuant to which, and on the terms and subject to the conditions of which, the PIPE Investors have collectively subscribed for 11,700,000 Class A Ordinary Shares, 11,600,000 shares of which were issued at a price of $10.00 per share for gross proceeds of $116.0 million and 100,000 shares of which were issued to placement agents of the PIPE in satisfaction of an aggregate of $1.0 million of fees owed by Helix to such placement agents.

Summary of Net Proceeds

The following table summarizes the elements of the net proceeds from the Business Combination:


	in thousands
Investments held in Trust Account	$	115,051
Less cash to cover redemptions of the Class A Ordinary Shares issued by Helix prior to the Closing Date	(80,842)
Plus PIPE investment	116,000
Less Helix transaction expense	(15,520)
of which accrued expenses	(5,798)
of which deferred IPO underwriting fee	(4,025)
of which other transaction expenses	(5,697)
Available Closing Date Cash	$	134,689

Summary of Ordinary Shares Issued

The following table summarizes the number of Ordinary Shares outstanding immediately following the consummation of the Business Combination:


Helix Acquisition Corp. Ordinary Shares prior to the Business Combination			14,805,000
Of which Class A Ordinary Shares (Helix management - IPO private placement shares)			430,000
Of which Class A Ordinary Shares redeemable			11,500,000
Of which Class B Ordinary Shares (Helix management - sponsor promote)			2,875,000
Less redemptions of the Class A Ordinary Shares issued by Helix prior to the Closing Date			(8,080,645)
Plus issuance of Helix Class A Ordinary Shares to PIPE Investors			11,700,000
Plus issuance of Helix Class A Ordinary Shares to BVF Shareholders			18,501,284
Total MoonLake Class A Ordinary Shares Outstanding at Closing			36,925,639
Plus issuance of Helix Class C Ordinary Shares to ML Parties (other than the BVF Shareholders)			15,775,472
Total MoonLake Class A and Class C Ordinary Shares Outstanding at Closing			52,701,111

Further information about the Business Combination can be found on Form S-1/A filed with the SEC on July 26, 2022, declared effective on August 2, 2022 and to the exhibits included therein, available at www.sec.gov.

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	Basis of Presentation and Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements include those of the Company and its subsidiaries, MoonLake AG and MoonLake Immunotherapeutics Ltd., after elimination of all intercompany accounts and transactions. The accompanying unaudited condensed consolidated financial statements and notes hereto have been prepared in conformity with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting and, therefore, omit or condense certain footnotes and other information normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) as set forth by the Financial Accounting Standards Board (“FASB”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the FASB. In the opinion of management, all adjustments necessary for a fair statement of the financial information, which are of a normal and recurring nature, have been made for the interim periods reported. Results of operations for the three and nine months ended September 30, 2022 and 2021 are not necessarily indicative of the results for the entire fiscal year or any other period. The unaudited condensed consolidated financial information for the three and nine months ended September 30, 2022 and 2021 have been prepared on the same basis as and should be read in conjunction with MoonLake AG’s audited financial statements and notes thereto for the year ended December 31, 2021 included in the final prospectus filed with the SEC pursuant to Rule 424(b)(3) on August 2, 2022. Pursuant to ASC 805, for financial accounting and reporting purposes, MoonLake AG was deemed the accounting acquirer and Helix was treated as the accounting acquiree, and the Business Combination was accounted for as a reverse recapitalization. Accordingly, the Business Combination was treated as the equivalent of MoonLake AG issuing shares for the net assets of Helix, accompanied by a recapitalization. The net assets of Helix were stated at historical costs, with no goodwill or other intangible assets recorded, and are consolidated with MoonLake AG’s financial statements on the Closing Date. In accordance with the Business Combination Agreement, the ML Parties received 33.638698 Ordinary Shares in the Company for every MoonLake AG Common Share or Series A Preferred Share (the “Exchange Ratio”). The BVF Shareholders received 18,501,284 Class A Ordinary Shares whereas the rest of the ML Parties (excluding the BVF Shareholders) received 15,775,472 Class C Ordinary Shares which can be converted into Class A Ordinary Shares at the discretion of the shareholder (refer to Note 11 — Shareholders’ Equity (Deficit) for further details on the classes of ordinary shares). The number of shares, and the number of shares within the net income (loss) per share held by the ML Parties in MoonLake AG prior to the Business Combination have been adjusted by the Exchange Ratio to reflect the equivalent number of ordinary shares in the Company (identified as “the equivalent of” throughout these condensed consolidated financial statements). Certain MoonLake AG shareholders (ML Parties other than the BVF Shareholders), did not exchange their shares in MoonLake AG for Class A Ordinary Shares in the Company and therefore continue to hold an economic interest in MoonLake AG and Class C Ordinary Shares in the Company. The Company recognized a noncontrolling interest equal to the ML Parties’ (other than the BVF Shareholders) proportionate interest in the net assets of MoonLake AG. All amounts are presented in U.S. Dollar (“$”), unless otherwise indicated. The term “Swiss franc” and “CHF” refer to the legal currency of Switzerland, and “€” refers to euros. Restatement of Consolidated Financial Statements as of and for the Three and Nine-months Ended September 30, 2021 On April 28, 2021, a shareholders’ agreement between MoonLake AG, its Series A investors, and its co-founders imposed a reverse vesting condition on 90% of the total 110,000 Common Shares (the equivalent of 3,700,257 Class C Ordinary Shares) held by each of the three co-founders. Therefore, 99,000 Common Shares (the equivalent of 3,330,231 Class C Ordinary Shares) held by each of the co-founders were subject to these restrictions and considered unvested (the “Restricted Founder Shares”). The Restricted Founder Shares vest on the 28th of each month at a rate of 4.166% over a period of two years until April 28, 2023. If, before the end of the vesting period, the contractual relationship of the relevant co-founders is terminated, MoonLake AG in first priority, or any third party designated by it, and the other shareholders in second priority pro rata to their shareholdings, shall have an option to purchase all or a pro rata portion of the leaver shares that are unvested on the day the termination becomes effective at nominal value of CHF 0.10 per share. The Restricted Founder Shares are legally outstanding and continue to have voting and dividend rights. Management had initially determined that the reverse vesting condition was necessary to induce the sale of the Series A Preferred Shares and did not contain a compensatory element. However, on December 13, 2021 a termination agreement was reached between one of the co-founders and MoonLake AG to terminate the co-founder’s contractual relationship and, as a result, 57,756 Common Shares (the equivalent of 1,942,837 Class C Ordinary Shares) were purchased by MoonLake AG. Management concluded that this termination agreement was reflective of the intention of the parties and therefore the substance of the previous agreement. As a result, management concluded that its accounting for the Restricted Founder Shares should have instead reflected a service condition and should be accounted for as a share-based compensation arrangement. Accounting for the Restricted Founder Shares as share-based compensation increased general and administrative expenses to reflect the recognition of the non-cash expense of the fair value of the Restricted Founder Shares at the grant date of April 28, 2021 over the two-year vesting period, and led to a corresponding increase in additional paid in capital. The previously unrecognized share-based compensation expense amounts to $1.8 million for three months ended September 30, 2021, and $3.1 for the period from inception to September 30, 2021, causing an increase in net loss, general and administrative expenses and additional paid-in capital of the same amount in the respective periods. Net loss per share was previously $(13.55) ((0.40), assuming the retroactive adjustment of the EPS denominator by multiplying MoonLake AG Common Shares by the Exchange Ratio) for the three months ended September 30, 2021, and $(70.56) ((2.10), assuming the retroactive adjustment of the EPS denominator by multiplying MoonLake AG Common Shares by the Exchange Ratio) for the period from inception to September 30, 2021. The increase in net loss, and exclusion of unvested Restricted Founder Shares in the denominator leads to corrected values of $(88.48) ((2.63), assuming the equivalent number of shares by applying the Exchange Ratio) for the three months ended September 30, 2021, and $(136.52) ((4.06), assuming the retroactive adjustment of the EPS denominator by multiplying MoonLake AG Common Shares by the Exchange Ratio) for the period from inception to September 30, 2021. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses. The significant judgments, estimates and assumptions relevant to the Company relate to: •determining whether the in-process research and development expenditure (“IPR&D”) has an alternative future use; •estimating the fair value of the portion of the aggregate purchase price relating to its own shares in connection with the acquisition of the in-license agreement; •determining assumptions used in determining the fair value of share-based compensation; and •estimating the recoverability of the deferred tax asset. The Company bases its judgments and estimates on various factors and information, which may include, but are not limited to, the Company’s forecasts and future plans, current economic conditions and observable market-based transactions of its own shares, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future results of operation may be affected. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates fair value. As of September 30, 2022, the Company considers $19.9 million of short-term marketable debt securities in the form of eurocommercial papers and certificates of deposit to be cash equivalents. As of December 31, 2021, the Company did not have any cash equivalents. Marketable securities and short-term investments The Company invests in short term marketable securities in the form of debt securities. At the time of purchase, the Company will assess whether such debt security should be classified as held-to-maturity or available-for-sale debt securities. Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity debt securities are carried at amortized cost, adjusted for accretion of discounts or amortization of premiums to maturity computed under the effective interest method. Such accretion or amortization is included in “Interest and dividend income.” Marketable debt securities not classified as held-to-maturity are classified as available-for-sale and reported at fair value. Net unrealized gains and losses on available-for-sale debt securities are excluded from the determination of earnings and are instead recognized in the “Accumulated other comprehensive income (loss)” component of shareholder’ equity (deficit) until realized. Realized gains and losses on available-for-sale debt securities are computed based upon the historical cost of these securities, using the specific identification method. A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and the cost of securities sold is determined using the specific-identification method. Marketable debt securities are classified as either “Cash and cash equivalents” or “Short‑term marketable debt securities” according to their maturity at the time of acquisition. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a large financial institution which, at times, may exceed the CHF 100,000 deposit protection limit. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. Further, the Company's investment strategy for cash (in excess of current business requirements) is set to invest in short-term securities. Management actively monitors credit risk in the investment portfolio. Credit risk exposures are controlled in accordance with policies approved by the board of directors to identify, measure, monitor and control credit risks. Fair Value Measurements The Company follows the guidance included in ASC 820, Fair Value Measurement. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There are three levels of inputs to fair value measurements: •Level 1, meaning the use of quoted prices for identical instruments in active markets; •Level 2, meaning the use of quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable; and •Level 3, meaning the use of unobservable inputs. Observable market data is used when available. Transfers between Levels 1, 2 or 3 within the fair value hierarchy are recognized at the end of the reporting period when the respective transaction occurred. Segment Information The Company operates as a single operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a stand-alone basis for the purposes of allocating resources, and assessing financial performance. Property and Equipment Property and equipment, net is stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method based on the estimated useful lives of three to five years. As of September 30, 2022, property and equipment, net relates to IT and office equipment. Research and Development Contract Costs and Accruals Research and development expenses include employee payroll, consulting, contract research and contract manufacturing costs attributable to research and development activities and are expensed as incurred. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development expenses in the period in which it is probable that a liability has been incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed. The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. The Company’s historical accrual estimates have not been materially different from the actual costs. Share-based Transaction Goods or services received in a share-based payment transaction are measured using a fair value-based measure. The Company measures and recognizes compensation expense for all share-based awards made to employees and directors based on estimated fair values. The fair value of employee share options is estimated on the date of grant using the Black-Scholes option pricing model. Share-based compensation expense is adjusted for forfeitures as they occur. Foreign Currency The functional currency of the Company and its subsidiaries is the U.S. dollar. Balances and transactions denominated in foreign currencies are converted as follows: monetary assets and liabilities are translated using exchange rates in effect at the balance sheet dates and non-monetary assets and liabilities are translated at historical exchange rates. Revenue and expenses are translated at the daily exchange rate on the respective accounting date. Gains or losses from foreign currency translation are included in the consolidated statement of operations. The Company recognized foreign currency transaction gain of $344,914 for the nine months ended September 30, 2022 (“the period ended September 30, 2022”), and a gain of $4,361 for the three months ended September 30, 2022. For the three and nine months ended September 30, 2021, MoonLake AG recognized a foreign currency transaction loss of $19,853 and $24,543 respectively. Income Taxes The Company accounts for income taxes by using the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Net Loss per Class A Ordinary Shares Basic net loss per Class A Ordinary Share is calculated using the two-class method under which earnings are allocated to both Class A Ordinary Shares and participating securities. Basic net loss per share is calculated by dividing the net loss attributable to Class A Ordinary Shares by the weighted-average number of Class A Ordinary Shares outstanding for the period. The diluted net loss per Class A Ordinary Share is computed by dividing the net loss using the weighted-average number of Class A Ordinary Shares and, if dilutive, potential Class A Ordinary Shares outstanding during the period. In periods in which the Company reports a net loss attributable to shareholders of Class A Ordinary Shares, diluted net loss per share attributable to shareholders of Class A Ordinary Shares is the same as basic net loss per share attributable to shareholders of Class A Ordinary Shares, since dilutive Class A Ordinary Shares are not assumed to be outstanding if their effect is anti-dilutive. Acquisitions The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first assessing whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. The Company acquired the Sonelokimab program (the "SLK Program") during the period ended December 31, 2021 and determined that substantially all of the fair value of the gross assets acquired related to IPR&D of SLK. Therefore, this transaction was accounted for as an asset acquisition. IPR&D represents incomplete technologies that the Company acquires, which at the time of acquisition, are still under development and have no alternative future use. The fair value of such technologies is expensed upon acquisition. A technology is considered to have an alternative future use if it is probable that the Company will use the asset in its current, incomplete state as it existed at the acquisition date, in another research and development project that has not yet commenced, and economic benefit is anticipated from that use. If a technology is determined to have an alternative future use, then the fair value of the program would be recorded as an asset on the balance sheet rather than expensed. Contingent consideration payments (for example milestone payments due upon the occurrence of a specific event) in asset acquisitions are recognized in the period in which it is probable that a liability has been incurred (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the cost in the asset acquired). Upon recognition of the contingent consideration payment, the amount is expensed if it relates to IPR&D or capitalized if it relates to a developed product which is generally considered to be when clinical trials have been completed and regulatory approval obtained. Future royalty payments due on net sales will be recognized in cost of goods sold when net sales are recognized. Pension Accounting The Company accounts for pension assets and liabilities in accordance with ASC 715, Compensation – Retirement Benefits, which requires the recognition of the funded status of pension plans in the Company’s consolidated balance sheet. The liability in respect to defined benefit pension plans is the projected benefit obligation calculated annually by independent actuaries using the projected unit credit method. The projected benefit obligation as of September 30, 2022 represents the actuarial present value of the estimated future payments required to settle the obligation that is attributable to employee services rendered before that date. Service costs for such pension plans, represented in the net periodic benefit cost, are included in the personnel expenses of the various functions where the employees are engaged. The other components of net benefit cost are included in the consolidated statement of operations separately from the service cost component, in “other income (expenses), net.” Plan assets are recorded at their fair value. Gains or losses arising from plan curtailments or settlements are accounted for at the time they occur. Any net pension asset is limited to the present value of the future economic benefits available to the Company in the form of refunds from the plan or expected reductions in future contributions to the plan. Actuarial gains and losses arising from differences between the actual and the expected return on plan assets are recognized in accumulated other comprehensive income (loss). Recently Issued Accounting Pronouncements not yet Adopted The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). As such the Company is eligible for exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including reduced reporting and extended transition periods to comply with new or revised accounting standards for public business entities. The Company has elected to avail itself of this exemption and, therefore, will not be subject to the timeline for adopting new or revised accounting standards for public business entities that are not emerging growth companies, and will follow the transition guidance applicable to private companies. In February 2016, the FASB issued ASU No. 2016-02, Leases Topic 842 (“ASU 2016-02”). The guidance in ASU 2016-02 supersedes the lease recognition requirements in ASC 840, Leases. ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases, along with additional qualitative and quantitative disclosures. ASU 2016-02 is effective for fiscal years beginning after December 15, 2021, and for interim periods within fiscal years beginning after December 15, 2022, with early adoption permitted. The Company has continued to account for the open-ended office lease agreement as an operating lease under the guidance prior to ASU 2016-02 through the consolidated statement of operations for the period ended December 31, 2021. In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements, which allows entities to elect a modified retrospective transition method where entities may continue to apply the existing lease guidance during the comparative periods and apply the new lease requirements through a cumulative effect adjustment in the period of adoptions rather than in the earliest period presented.

Risks and Liquidity	9 Months Ended
Risks and Liquidity	Sep. 30, 2022
Risks and Uncertainties [Abstract]
Risks and Liquidity	Risks and Liquidity Going Concern, Liquidity and Capital Resources The Company incurred a loss of $48.0 million for the nine months ended September 30, 2022. As of September 30, 2022, the Company’s current assets exceeded its current liabilities by $82.5 million. The Company had $41.2 million of cash and cash equivalents, of which $19.9 million relate to investments in short-term marketable debt securities with an original maturity of three months or less at the date of purchase, and $42.3 million of short-term marketable debt securities with an original maturity of more than three months at the date of purchase. Management believes that the Company has sufficient capital to fund its operations and capital expenditures into the second half of 2024. Coronavirus Pandemic In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic which continues to evolve. To date, the impact of COVID-19 on the Company’s business, operations and development timelines has been limited. However, the future impact of COVID-19 on the Company's business is uncertain. The Company will continue to actively monitor the evolving situation related to COVID-19 and may take further actions that alter its operations, including those that may be required by Switzerland state or local authorities, or that the Company determines are in the best interests of its employees and other third parties with whom the Company does business. At this point, the extent to which COVID-19 may affect the Company's future business, operations and development timelines and plans, including the resulting impact on our expenditures and capital needs, remains uncertain and the Company may experience disruptions.

Fair Value Measurements

9 Months Ended

Sep. 30, 2022

Fair Value Disclosures [Abstract]

Fair Value Measurements

The following table presents the Company’s short-term marketable debt securities by level within the fair value hierarchy:


	September 30, 2022
	Level 1		Level 2		Level 3		Total
Eurocommercial Papers	$	32,407,888	$	—	$	—	$	32,407,888
Certificates of Deposit	9,846,900		—		—		9,846,900
Total	$	42,254,788	$	—	$	—	$	42,254,788

There were no Eurocommercial Papers, Certificates of Deposit or other assets measured at fair value as at December 31, 2021.

Cash, accounts payable and accrued liabilities approximate their fair values as of September 30, 2022 and December 31, 2021, due to their short-term nature. Pension plan assets fair value is determined based on Level 2 inputs.

Investments, Debt and Equity Securities [Abstract]

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Investments

9 Months Ended

Sep. 30, 2022

Investments

The fair value and amortized cost of investments in short-term marketable debt securities by major security type as of September 30, 2022 are as follows:


	Amortized cost		Gross unrealized gains		Gross unrealized losses		Fair value
Eurocommercial Papers	$	52,287,157	$	80,994	$	(16,263)	$	52,351,888
Certificates of Deposit	9,834,625		12,275		—		9,846,900
Total	$	62,121,782	$	93,269	$	(16,263)	$	62,198,788
Of which classified within cash and cash equivalents	19,895,762		48,238		—		19,944,000
Of which classified within short-term marketable debt securities	42,226,020		45,031		(16,263)		42,254,788

The following table presents the changes in fair values of the Company’s short-term marketable debt securities, classified as level 1 financial assets (in thousands):


Beginning balance, January 1, 2022	$	—
Other comprehensive income before reclassifications	95,815
Amounts reclassified from accumulated other comprehensive income	(18,809)
Net current-period other comprehensive income	77,006
Ending balance, September 30, 2022	$	77,006

As of September 30, 2022, the Company’s marketable debt securities maturities are all due within one year.

Prepaid expenses

9 Months Ended

Sep. 30, 2022

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Prepaid expenses

Prepaid Expenses


	September 30, 2022		December 31, 2021
Advances on non-clinical research and clinical development services	$	2,208,728	$	547,586
Advances on insurances	2,042,275		23,141
Advances on supply and manufacturing services	83,559		750,622
Other prepayments	144,632		127,747




Total	$	4,479,194	$	1,449,096

Prepaid expenses as of September 30, 2022 primarily relate to services expected to be received within the next 12 months.

Trade and other payables

9 Months Ended

Sep. 30, 2022

Trade and other payables

Trade and Other Payables


	September 30, 2022		December 31, 2021
Supply and manufacturing fees payable	$	523,991	$	183,298
Legal and intellectual property (“IP”) advisory fees payable	155,532		1,233,070
Research and development services	149,161		50,088
Other consulting and advisory services	77,741		71,938


Other payables	149,828		30,896
Total	$	1,056,253	$	1,569,290

Accrued Expenses and Other Current Liabilities


	September 30, 2022		December 31, 2021
Research and development services	$	3,281,331	$	—
Bonuses and related employees compensation expenses	865,882		1,419,137
License fees	520,948		2,055,687
Consultant and other fees	154,806		49,211
Legal fees	77,895		930,354
Tax liabilities	61,608		63,922
Total	$	4,962,470	$	4,518,311

Accrued expenses and other current liabilities

9 Months Ended

Sep. 30, 2022

Accrued expenses and other current liabilities

Trade and Other Payables


	September 30, 2022		December 31, 2021
Supply and manufacturing fees payable	$	523,991	$	183,298
Legal and intellectual property (“IP”) advisory fees payable	155,532		1,233,070
Research and development services	149,161		50,088
Other consulting and advisory services	77,741		71,938


Other payables	149,828		30,896
Total	$	1,056,253	$	1,569,290

Accrued Expenses and Other Current Liabilities


	September 30, 2022		December 31, 2021
Research and development services	$	3,281,331	$	—
Bonuses and related employees compensation expenses	865,882		1,419,137
License fees	520,948		2,055,687
Consultant and other fees	154,806		49,211
Legal fees	77,895		930,354
Tax liabilities	61,608		63,922
Total	$	4,962,470	$	4,518,311

Employee Benefit Plans

9 Months Ended

Sep. 30, 2022

Retirement Benefits [Abstract]

Employee benefit plans

Employee Benefit Plans

The Company operates a defined benefit pension plan in Switzerland (“the Plan”) and a defined contribution pension plan in the United Kingdom, in accordance with local regulations and practices. As of September 30, 2022 the Plan covers the Company’s employees in Switzerland with benefits in the event of death, disability, retirement, or termination of employment.

Components of Net Periodic Benefit Cost under the Plan


	Three months ended September 30, 2022		Three months ended September 30, 2021		Nine Months Ended September 30, 2022		Nine Months Ended September 30, 2021
Service cost	$	112,222	$	11,423	$	338,173	$	11,423
Interest cost	1,258		—		3,791		—
Expected return on plan assets	(3,862)		—		(11,637)		—

Amortization of unrecognized loss	451		—		1,361		—

Total Net Periodic Benefit Cost	$	110,069	$	11,423	$	331,688	$	11,423

The components of net periodic benefit cost other than the service cost component are included in general and administrative expense in the Company's unaudited condensed consolidated statements of operations.

Employer Contributions under the Plan

For the nine months ended September 30, 2022, $103,873 (CHF 98,806) of contributions were made to the Plan. The Company presently anticipates contributing an additional estimated amount of $33,757 (CHF 32,609) to fund the Plan in 2022 for a total of $137,630 (CHF 131,415).

Shareholders’ Equity (Deficit)

9 Months Ended

Sep. 30, 2022

Equity [Abstract]

Shareholders’ Equity (Deficit)

As a result of the Business Combination, the Company has retroactively restated the share numbers prior to April 5, 2022 to give effect to the Exchange Ratio.


	Series A Preferred Shares(1)		Common Shares(1)		Common Shares Held In Treasury(2)	Class A Ordinary Shares(3)		Class C Ordinary Shares(3)		Total Number of Shares
	Authorized	Issued	Authorized	Issued	Issued	Authorized	Issued	Authorized	Issued	Authorized	Issued and Outstanding
Balance - December 31, 2021	22,880,908	22,880,908	13,119,092	12,161,331	(1,942,837)	—	—	—	—	36,000,000	33,099,402
Share-based payment under the equity incentive plan ESPP	—	—	—	—	1,177,354	—	—	—	—	—	1,177,354
Balance - March 31, 2022	22,880,908	22,880,908	13,119,092	12,161,331	(765,483)	—	—	—	—	36,000,000	34,276,756
Issuance of Class A Ordinary Shares upon Business Combination	—	—	—	—	—	500,000,000	18,424,355	100,000,000	—	600,000,000	18,424,355
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination	(22,880,908)	(22,880,908)	(13,119,092)	(12,161,331)	765,483	—	18,501,284	—	15,775,472	(36,000,000)	—
Balance - June 30, 2022	—	—	—	—	—	500,000,000	36,925,639	100,000,000	15,775,472	600,000,000	52,701,111
Balance - September 30, 2022	—	—	—	—	—	500,000,000	36,925,639	100,000,000	15,775,472	600,000,000	52,701,111

(1) Fully paid-in registered shares with a par value of CHF 0.10

(2) Registered shares with a par value of CHF 0.10 held in treasury

(3) Fully paid-in registered shares with a par value of $0.0001

As of September 30, 2022, the Company had the following classes of shares:

Class A Ordinary Shares

On April 6, 2021, the Company's Class A Ordinary Shares began trading on the Nasdaq Stock Market under the symbol “MLTX.” As of September 30, 2022, there were 36,925,639 Class A Ordinary Shares issued or outstanding. The Company is authorized to issue up to 500,000,000 Class A Ordinary Shares, par value $0.0001 per share. Holders of Class A Ordinary Shares are entitled to one vote for each share.

Class C Ordinary Shares

On the Closing Date, the Company issued 15,775,472 Class C Ordinary Shares to the ML Parties (other than the BVF Shareholders) in an amount equivalent to the ML Parties' (other than the BVF Shareholders) 468,968 MoonLake AG Common Shares multiplied by the Exchange Ratio. As of September 30, 2022, there were 15,775,472 Class C Ordinary Shares issued and outstanding. The Company is authorized to issue up to 100,000,000 Class C Ordinary Shares, with a par value $0.0001 per share. Each Class C Ordinary Share entitles the holders thereof to one vote per share, but carries no economic rights.

At the Closing, MoonLake, MoonLake AG and each ML Party entered into a Restated and Amended Shareholders' Agreement (the “A&R Shareholders' Agreement”). With the intent to approximate the rights, obligations and restrictions that an ML Party would enjoy if it were a holder of Class A Ordinary Shares, the A&R Shareholders’ Agreement (i) imposes certain transfer and other restrictions on the ML Parties, (ii) provides for the waiver of certain statutory rights and (iii) establishes certain mechanics whereby MoonLake and each of the ML Parties are able to effect the conversion of MoonLake AG Common Shares and Class C Ordinary Shares into a number of Class A Ordinary Shares equal to the Exchange Ratio. Subsequent to September 30, 2022, a number of MoonLake AG Common Shares and Class C Ordinary Shares were converted into MoonLake Immunotherapeutics Class A Ordinary Shares (please see Note 16 - Subsequent Events for additional information). The foregoing description of the A&R Shareholders’ Agreement is not complete and is qualified in its entirety by reference to the full text of the A&R Shareholders’ Agreement.

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

Share-Based Payment Arrangement [Abstract]

Net loss per share

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

Net loss per share

Net Loss per Share

As a result of the Business Combination, the Company has retroactively restated the weighted average number of outstanding prior to April 5, 2022 to give effect to the Exchange Ratio.

The following table sets forth the loss per share calculations for the three and nine months ended September 30, 2022 compared to the three and nine months ended September 30, 2021:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Numerator
Net loss attributable to controlling interests shareholders	$	(10,110,452)	$	(6,288,056)	$	(32,865,429)	$	(39,325,510)

Denominator
Total weighted average number of outstanding shares	36,925,639		2,390,587		25,830,560		9,689,627

Net loss per share – basic and diluted	$	(0.27)	$	(2.63)	$	(1.27)	$	(4.06)

The weighted average number of shares used to calculate the net loss per share – basic for the three months and the nine months ended September 30, 2022 excludes 15,775,472 Class C Ordinary Shares as they do not carry economic rights.

In the event that ML Parties (other than the BVF Shareholders) elected to convert their 468,968 MoonLake AG Common Shares into 15,775,472 Class A Ordinary Shares on the Closing Date, the weighted average number of shares outstanding would have been 52,701,111 and 36,116,399 for the three and nine months ended September 30, 2022, resulting in a respective net loss per share of $(0.28) and $(1.33). Upon conversion, 15,775,472 Class C Ordinary Shares would be forfeited and there would no longer be any noncontrolling interests.

Upon conversion, the Company's number of Class A Ordinary Shares outstanding would be 52,701,111 as of November 14, 2022, the date the unaudited condensed consolidated financial statements were issued.

Share-based Compensation

9 Months Ended

Sep. 30, 2022

Share-based Compensation

As at September 30, 2022 the Company had the following share-based compensation arrangements:

a.Restricted Founder Shares – created in April 2021 by MoonLake AG;

b.The Employee Share Participation Plan (“ESPP”) – created in July 2021 by MoonLake AG;

c.The Employee Stock Option Plan (“ESOP”) – created in July 2021 by MoonLake AG;

d.MoonLake Immunotherapeutics 2022 Equity Incentive Plan – created in April 2022 by MoonLake Immunotherapeutics.

The purpose of the arrangements is to attract and retain the best available personnel and to provide participants with additional incentive to increase their efforts on behalf and in the best interest of the Company and its subsidiaries.

As a result of the Business Combination, the Company has adjusted the share numbers related to the Restricted Founder Shares and Common Shares (under the ESPP and ESOP) prior to the Business Combination by the Exchange Ratio. The assumptions used in the valuation of the awards granted prior to Closing of the Business Combination have not been adjusted. The reference to “Common Shares” in this Note 13 refers to shares in MoonLake AG.

MoonLake AG's compensation plans are settled with Common Shares, and with a number of Class C Ordinary Shares determined multiplying the Common Shares by the Exchange Ratio. The owners of Common Shares have the right to exchange their Common Shares for a number of Class A Ordinary Shares derived using the Exchange Ratio. In the event MoonLake AG shareholders elect to exchange their Common Shares, such MoonLake AG shareholder forfeits a number of Class C Ordinary Shares equal to the number of Class A Ordinary Shares issued (please see Note 11 — Shareholders’ Equity (Deficit) - Class C Ordinary Shares).

For the three and nine months ended September 30, 2022, the Company has recognized an increase in equity in the condensed consolidated balance sheet, and share-based compensation expense in the condensed consolidated statement of operations of $2.6 million and $7.1 million respectively. The share-based compensation expense was driven by the following share-based compensation plans and programs:


Compensation Plan	Three months ended September 30, 2022		Three months ended September 30, 2021		Nine Months Ended September 30, 2022		Nine Months Ended September 30, 2021
MoonLake AG Restricted Founder Shares	$	1,210,191	$	1,815,078	$	3,618,226	$	3,065,443
ESPP	1,080,441		39,436		2,829,635		39,436


ESOP	169,907		1,313		370,634		1,313


MoonLake Immunotherapeutics 2022 Equity Incentive Plan	124,621		—		239,760		—
Total share-based compensation expense1	$	2,585,160	$	1,855,827	$	7,058,255	$	3,106,192
Of which: included in R&D expense	161,987		5,461		380,917		5,461
Of which: included in G&A expense	2,423,173		1,850,366		6,677,338		3,100,731

(1) In order to acquire the in-licensing agreement, the Company transferred to Merck KGaA, Darmstadt, Germany on April 28, 2021: (i) a cash consideration of $25.0 million; and (ii) an equity consideration of 99,000 Common Shares (the equivalent of 3,330,231 Class C Ordinary Shares) for a total payment of $1. The fair value of the equity consideration of $4,851,000 was recorded as share-based portion for the in-licensing agreement for the IPR&D asset (“In-licensing Agreement”) and does not belong to any compensation plan.

As of September 30, 2022, 22,756 treasury shares (the equivalent of 765,482 Class C Ordinary Shares) and 14,596 Common Shares (the equivalent of 490,990 Class C Ordinary Shares) issuable from the authorized conditional capital shares remain available for future grants under the ESPP and the ESOP by MoonLake AG.

MoonLake AG - Restricted Founder Shares

On April 28, 2021, the shareholders’ agreement between the co-founders, the Series A investors and MoonLake AG imposed a reverse vesting condition on 90% of the total 110,000 Common Shares (the equivalent of 3,700,257 Class C Ordinary Shares) held by each of the three co-founders. Therefore, 99,000 Common Shares (the equivalent of 3,330,231 Class C Ordinary Shares) held by each of the co-founders were subject to these restrictions and considered unvested. The Restricted Founder Shares vest on the 28th of each month at a rate of 4.166% over a period of two years until April 28, 2023. If, before the end of the vesting period, the contractual relationship of the relevant co-founders is terminated, MoonLake AG in first priority, or any third party designated by it, and the other shareholders in second priority pro rata to their shareholdings, shall have an option to purchase all or a pro rata portion of the leaver shares that are unvested on the day the termination becomes effective at nominal value of CHF 0.10 (equivalent of $0.0001) per share.

The assumptions used in the valuation of the Restricted Founder Shares awarded are summarized below:


Grant date			4/28/2021
Estimated fair value per share of Restricted Founder Shares on the grant date ($) (1)			49
Estimated fair value of Restricted Founder Shares on the resignation date of one of the co-founders of MoonLake AG ($) (2)			336.39
Purchase price (CHF)			0.10
(1) MoonLake AG estimated the fair value of the Restricted Founder Shares with reference to the market-based transaction with the other Series A Preferred Shares Investors (refer to Note 9 of the audited consolidated financial statements for the year ended December 31, 2021).
(2) MoonLake AG estimated the fair value of the Restricted Founder Shares at co-founder’s resignation date by dividing the Company Enterprise Value ($360,000,000) as defined by the Business Combination Agreement by the Company’s fully diluted shares (1,070,196).








Grants awarded
Program			Restricted Founder Shares
Awards outstanding at January 1, 2022			4,440,309



Awards vested for the nine months ended September 30, 2022			(2,497,673)
Awards outstanding at September 30, 2022			1,942,634

As of September 30, 2022, MoonLake AG had $2.8 million of total unrecognized compensation expense related to the Restricted Founder Shares that will be recognized by April 28, 2023 with a monthly compensation expense of $403,416.

Employee Share Participation Plan (ESPP) 2021-2025 - MoonLake AG

The ESPP grants will vest 25% on each anniversary of the grant date. In the event of a termination of contractual relationship between the Company and the entitled employee, the awards can be deemed forfeited by MoonLake AG if certain conditions are met. Awards feature an accelerated vesting condition linked to a “Change of Control”, defined as any transfer of shares that results in the proposed acquirer holding more than 50% of the then issued share capital of MoonLake AG or the Company, as the case may be, where the grants will be deemed fully vested on the earlier of (i) 12 months (or such shorter period determined by the board of directors) after the occurrence of a “change of control” or (ii) the date after the occurrence of the change of control on which a termination notice is served to the participant by MoonLake AG (other than a bad leaver termination, described below) or by the participant for good cause (as defined under Swiss law or any other applicable foreign law). For awards made after September 30, 2021, the Closing of the Business Combination between MoonLake AG and Helix does not qualify as a Change of Control.

The assumptions used in the valuation of the grants awarded under the ESPP for the nine months ended September 30, 2022 are summarized below:


ESPP 2021
Assumptions for the awards issued during the nine months ended September 30, 2022
Grant dates			01/18/2022
Estimated fair value per share of Common Shares on the grant date ($) (1)			336.39
Purchase price (CHF)			0.10
(1) MoonLake AG estimated the fair value of the Common Shares by dividing the Company Enterprise Value ($360,000,000) as defined by the Business Combination Agreement by the Company’s fully diluted shares (1,070,196).

Grants awarded
Program			ESPP
Awards outstanding at January 1, 2022			1,060,561



Awards granted for the nine months ended September 30, 2022			1,177,354
Awards outstanding at September 30, 2022			2,237,915
Awards vested at September 30, 2022			265,241

As of September 30, 2022, MoonLake AG had $10.6 million of total unrecognized compensation expense related to the ESPP that will be recognized over the weighted average period of 2.02 years.

Employee Stock Option Plan (ESOP) 2021-2025 - MoonLake AG

The ESOP grants will vest 25% on each anniversary of the grant date. In the event of a termination of contractual relationship between the Company and the entitled employee, options can be deemed forfeited by MoonLake AG if certain conditions are met. Awards feature an accelerated vesting condition linked to a “Change of Control”, defined as any transfer of shares that results in the proposed acquirer holding more than 50% of the then issued share capital of MoonLake AG or the Company, as the case may be, where the grants will be deemed fully vested on the earlier of (i) 12 months (or such shorter period determined by the board of directors) after the occurrence of a “change of control” or (ii) the date after the occurrence of the change of control on which a termination notice is served to the participant by MoonLake AG (other than a bad leaver termination, described below) or by the participant for good cause (as defined under Swiss law or any other applicable foreign law). For awards made after September 30, 2021, the Closing of the Business Combination between MoonLake AG and Helix does not qualify as a Change of Control.


Weighted average assumptions for the awards issued during the nine months ended September 30, 2022
Grant dates			5/1/2022, 6/22/2022
Estimated fair value of the option on the grant date using Black-Scholes model ($) (1)			172.57
Exercise price (CHF)			27.25
Expected term of the award on the grant date (years) (2)			6
Expected volatility of the share price (3)			0.75
Risk-free interest rate (4)			3%
Expected dividend rate			0
(1) MoonLake AG estimated the fair value of the Common Shares multiplying the MoonLake Immunotherapeutics closing date trading share price on the grant date by the Exchange Ratio. (2) The expected term represents the period that share-based awards are expected to be outstanding. (3) The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company’s industry. (4) The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.


Grants awarded
Program			ESOP
Awards outstanding at January 1, 2022			224,033



Awards granted for the nine months ended September 30, 2022			242,737
Awards outstanding at September 30, 2022			466,770
Awards exercisable at September 30, 2022			23,311

As of September 30, 2022, MoonLake AG had $2.0 million of total unrecognized compensation expense related to the ESOP that will be recognized over the weighted average period of 2.89 years.

MoonLake Immunotherapeutics 2022 Equity Incentive Plan

On April 5, 2022 (the “Effective Date”) the Company created the “MoonLake Immunotherapeutics 2022 Equity Incentive Plan” (the “Equity Incentive Plan”) to promote and closely align the interests of employees, officers, non-employee directors and other service providers of MoonLake Immunotherapeutics and its shareholders by providing share-based compensation and other performance-based compensation.

The Equity Incentive Plan provides for the grant of options, stock appreciation rights, restricted stock units, restricted stock and other share-based awards and for incentive bonuses, which may be paid in cash, Common Shares or a combination thereof, as determined by the compensation committee of the board of directors or such other committee as designated by the board of directors to administer the Equity Incentive Plan. The Equity Incentive Plan shall remain available for the grant of awards until the 10th anniversary of the Effective Date.

On April 6, 2022, the Company granted 180,000 options under the Equity Incentive Plan, each option representing the right to acquire one Class A Ordinary Share, par value $0.0001 per share, of MoonLake. The options will vest one-third on each April 6, 2023, April 6, 2024 and April 6, 2025.

During the nine months ended September 30, 2022, no other grants were awarded under the Equity Incentive Plan.


Grant date			4/6/2022
Estimated fair value of the option on the grant date using Black-Scholes model ($)			8.25
Exercise price ($)			12.25
Expected term of the award on the grant date (years)			6
Expected volatility of the share price			75%
Risk-free interest rate			3%
Expected dividend rate			-


Grants awarded
Program	MoonLake Immunotherapeutics 2022 Equity Incentive Plan
Awards outstanding at January 1, 2022		—



Awards granted for the nine months ended September 30, 2022		180,000
Awards outstanding at September 30, 2022		180,000
Awards exercisable at September 30, 2022		—

As of September 30, 2022, the Company had $1.2 million of total unrecognized compensation expense related to the Equity Incentive Plan that will be recognized over the weighted average period of 2.52 years.

Income taxes	9 Months Ended
Income taxes	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income taxes	Income TaxesThe Company's effective tax rate (“ETR”) was 0.1% and 0.1% for each of the three and nine months ended September 30, 2022, respectively, and 0.0% for each of the three and nine months ended September 30, 2021. The Company is not aware of any items that would cause the quarterly or period-to-date ETR to be significantly different from the Company's annual ETR. The difference between the income tax provision that would be derived by applying the statutory rate to the Company's loss before income taxes and the income tax provision recorded was primarily attributable to the change in the valuation allowance. The Company continues to incur losses for the Cayman Island and Swiss entity and its ability to utilize the deferred tax asset related to the tax losses is not considered more likely than not.

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Summary of Net Proceeds and Ordinary Shares Issued

Commitment and Contingencies	9 Months Ended
Commitment and Contingencies	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitment and Contingencies	Commitments and Contingencies Commitments The Company has entered into agreements as of September 30, 2022 primarily in regard to advancement of clinical and non-clinical research program expenses, production of drug substance and technology transfer of the drug product process for SLK. As of September 30, 2022, the total committed amount under these agreements not yet recognized amounted to $37.4 million. On April 2021, MoonLake AG acquired the SLK program, which includes contractual milestone payments related to the achievement of pre-specified research, development, regulatory and commercialization events and indemnification provisions, which are common in such agreements. Pursuant to the agreements, the Company is obligated to make research and development and regulatory milestone payments upon the occurrence of certain events and royalty payments based on net sales. Subject to the terms of the license, additional milestone payments of up to €302.1 million ($295.5 million using a September 30, 2022 exchange rate) are potentially payable, of which less than 1 percent being due upon initiation of the next clinical trial and the remainder being due upon satisfying specific milestones related to regulatory filing acceptance, first commercial sales, and aggregate annual net sales. The milestone payments are payable in cash. Milestone payments due prior to obtaining regulatory approval will be recorded as research and development expense upon determination that a milestone payment is probable to occur. Milestone payments due after obtaining regulatory approval will be capitalized when and if incurred. The Company will use commercially reasonable efforts to cause the milestones to occur. However, if the Company reasonably determines that a technical failure or commercial failure has occurred with respect to all or a part of the SLK Program, the Company, at its sole discretion, can terminate all or part of the SLK Program. In addition, the In-licensing Agreement requires the Company to pay royalties within the range of low to mid-teen percent of net sales. Royalties will be recognized in the consolidated statement of operations when net sales are recognized. The Company has committed to a lease contract with a term that commenced on November 1, 2021. We have accounted for this open-ended office lease arrangement as an operating lease under the guidance prior to ASU 2016-02, Leases Topic 842 through the consolidated statement of operations for the three and nine months period ended June 30, 2022. The future lease commitments in the amount of $0.3 million relate to office contract for our headquarters in Zug, Switzerland and reflects minimum payments due.

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventsPartial Share ConversionOn October 6, 2022, pursuant to the A&R Shareholders’ Agreement, an ML Party submitted an Exchange Notice to the Company, pursuant to which such ML Party effected the conversion of 61,000 MoonLake AG Common Shares and 2,051,961 Class C Ordinary Shares into 2,051,961 Class A Ordinary Shares using the Exchange Ratio. Please refer to Note 11 – Shareholders’ Equity (Deficit) – Class C Ordinary Shares for more information regarding the conversion mechanics.

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of presentation	The accompanying unaudited condensed consolidated financial statements include those of the Company and its subsidiaries, MoonLake AG and MoonLake Immunotherapeutics Ltd., after elimination of all intercompany accounts and transactions. The accompanying unaudited condensed consolidated financial statements and notes hereto have been prepared in conformity with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting and, therefore, omit or condense certain footnotes and other information normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) as set forth by the Financial Accounting Standards Board (“FASB”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the FASB. In the opinion of management, all adjustments necessary for a fair statement of the financial information, which are of a normal and recurring nature, have been made for the interim periods reported. Results of operations for the three and nine months ended September 30, 2022 and 2021 are not necessarily indicative of the results for the entire fiscal year or any other period. The unaudited condensed consolidated financial information for the three and nine months ended September 30, 2022 and 2021 have been prepared on the same basis as and should be read in conjunction with MoonLake AG’s audited financial statements and notes thereto for the year ended December 31, 2021 included in the final prospectus filed with the SEC pursuant to Rule 424(b)(3) on August 2, 2022. Pursuant to ASC 805, for financial accounting and reporting purposes, MoonLake AG was deemed the accounting acquirer and Helix was treated as the accounting acquiree, and the Business Combination was accounted for as a reverse recapitalization. Accordingly, the Business Combination was treated as the equivalent of MoonLake AG issuing shares for the net assets of Helix, accompanied by a recapitalization. The net assets of Helix were stated at historical costs, with no goodwill or other intangible assets recorded, and are consolidated with MoonLake AG’s financial statements on the Closing Date. In accordance with the Business Combination Agreement, the ML Parties received 33.638698 Ordinary Shares in the Company for every MoonLake AG Common Share or Series A Preferred Share (the “Exchange Ratio”). The BVF Shareholders received 18,501,284 Class A Ordinary Shares whereas the rest of the ML Parties (excluding the BVF Shareholders) received 15,775,472 Class C Ordinary Shares which can be converted into Class A Ordinary Shares at the discretion of the shareholder (refer to Note 11 — Shareholders’ Equity (Deficit) for further details on the classes of ordinary shares). The number of shares, and the number of shares within the net income (loss) per share held by the ML Parties in MoonLake AG prior to the Business Combination have been adjusted by the Exchange Ratio to reflect the equivalent number of ordinary shares in the Company (identified as “the equivalent of” throughout these condensed consolidated financial statements). Certain MoonLake AG shareholders (ML Parties other than the BVF Shareholders), did not exchange their shares in MoonLake AG for Class A Ordinary Shares in the Company and therefore continue to hold an economic interest in MoonLake AG and Class C Ordinary Shares in the Company. The Company recognized a noncontrolling interest equal to the ML Parties’ (other than the BVF Shareholders) proportionate interest in the net assets of MoonLake AG. All amounts are presented in U.S. Dollar (“$”), unless otherwise indicated. The term “Swiss franc” and “CHF” refer to the legal currency of Switzerland, and “€” refers to euros.
Use of estimates	The preparation of financial statements in conformity with U.S. GAAP requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses. The significant judgments, estimates and assumptions relevant to the Company relate to: •determining whether the in-process research and development expenditure (“IPR&D”) has an alternative future use; •estimating the fair value of the portion of the aggregate purchase price relating to its own shares in connection with the acquisition of the in-license agreement; •determining assumptions used in determining the fair value of share-based compensation; and •estimating the recoverability of the deferred tax asset. The Company bases its judgments and estimates on various factors and information, which may include, but are not limited to, the Company’s forecasts and future plans, current economic conditions and observable market-based transactions of its own shares, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future results of operation may be affected.
Cash and cash equivalents	The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates fair value. As of September 30, 2022, the Company considers $19.9 million of short-term marketable debt securities in the form of eurocommercial papers and certificates of deposit to be cash equivalents. As of December 31, 2021, the Company did not have any cash equivalents.
Marketable securities and short-term investments	The Company invests in short term marketable securities in the form of debt securities. At the time of purchase, the Company will assess whether such debt security should be classified as held-to-maturity or available-for-sale debt securities. Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity debt securities are carried at amortized cost, adjusted for accretion of discounts or amortization of premiums to maturity computed under the effective interest method. Such accretion or amortization is included in “Interest and dividend income.” Marketable debt securities not classified as held-to-maturity are classified as available-for-sale and reported at fair value. Net unrealized gains and losses on available-for-sale debt securities are excluded from the determination of earnings and are instead recognized in the “Accumulated other comprehensive income (loss)” component of shareholder’ equity (deficit) until realized. Realized gains and losses on available-for-sale debt securities are computed based upon the historical cost of these securities, using the specific identification method. A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and the cost of securities sold is determined using the specific-identification method. Marketable debt securities are classified as either “Cash and cash equivalents” or “Short‑term marketable debt securities” according to their maturity at the time of acquisition.
Concentration of credit risk	Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a large financial institution which, at times, may exceed the CHF 100,000 deposit protection limit. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. Further, the Company's investment strategy for cash (in excess of current business requirements) is set to invest in short-term securities. Management actively monitors credit risk in the investment portfolio. Credit risk exposures are controlled in accordance with policies approved by the board of directors to identify, measure, monitor and control credit risks.
Fair value measurements	The Company follows the guidance included in ASC 820, Fair Value Measurement. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There are three levels of inputs to fair value measurements: •Level 1, meaning the use of quoted prices for identical instruments in active markets; •Level 2, meaning the use of quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable; and •Level 3, meaning the use of unobservable inputs. Observable market data is used when available. Transfers between Levels 1, 2 or 3 within the fair value hierarchy are recognized at the end of the reporting period when the respective transaction occurred.
Segment information	The Company operates as a single operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a stand-alone basis for the purposes of allocating resources, and assessing financial performance.
Property and equipment	Property and equipment, net is stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method based on the estimated useful lives of three to five years. As of September 30, 2022, property and equipment, net relates to IT and office equipment.
Research and development contract costs and accruals	Research and development expenses include employee payroll, consulting, contract research and contract manufacturing costs attributable to research and development activities and are expensed as incurred. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development expenses in the period in which it is probable that a liability has been incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed. The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. The Company’s historical accrual estimates have not been materially different from the actual costs.
Share-based transaction	Goods or services received in a share-based payment transaction are measured using a fair value-based measure. The Company measures and recognizes compensation expense for all share-based awards made to employees and directors based on estimated fair values. The fair value of employee share options is estimated on the date of grant using the Black-Scholes option pricing model. Share-based compensation expense is adjusted for forfeitures as they occur.
Foreign currency	The functional currency of the Company and its subsidiaries is the U.S. dollar. Balances and transactions denominated in foreign currencies are converted as follows: monetary assets and liabilities are translated using exchange rates in effect at the balance sheet dates and non-monetary assets and liabilities are translated at historical exchange rates. Revenue and expenses are translated at the daily exchange rate on the respective accounting date.Gains or losses from foreign currency translation are included in the consolidated statement of operations.
Income taxes	The Company accounts for income taxes by using the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.
Net loss per Class A Ordinary Shares	Basic net loss per Class A Ordinary Share is calculated using the two-class method under which earnings are allocated to both Class A Ordinary Shares and participating securities. Basic net loss per share is calculated by dividing the net loss attributable to Class A Ordinary Shares by the weighted-average number of Class A Ordinary Shares outstanding for the period. The diluted net loss per Class A Ordinary Share is computed by dividing the net loss using the weighted-average number of Class A Ordinary Shares and, if dilutive, potential Class A Ordinary Shares outstanding during the period.In periods in which the Company reports a net loss attributable to shareholders of Class A Ordinary Shares, diluted net loss per share attributable to shareholders of Class A Ordinary Shares is the same as basic net loss per share attributable to shareholders of Class A Ordinary Shares, since dilutive Class A Ordinary Shares are not assumed to be outstanding if their effect is anti-dilutive.
Acquisitions	The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first assessing whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. The Company acquired the Sonelokimab program (the "SLK Program") during the period ended December 31, 2021 and determined that substantially all of the fair value of the gross assets acquired related to IPR&D of SLK. Therefore, this transaction was accounted for as an asset acquisition. IPR&D represents incomplete technologies that the Company acquires, which at the time of acquisition, are still under development and have no alternative future use. The fair value of such technologies is expensed upon acquisition. A technology is considered to have an alternative future use if it is probable that the Company will use the asset in its current, incomplete state as it existed at the acquisition date, in another research and development project that has not yet commenced, and economic benefit is anticipated from that use. If a technology is determined to have an alternative future use, then the fair value of the program would be recorded as an asset on the balance sheet rather than expensed. Contingent consideration payments (for example milestone payments due upon the occurrence of a specific event) in asset acquisitions are recognized in the period in which it is probable that a liability has been incurred (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the cost in the asset acquired). Upon recognition of the contingent consideration payment, the amount is expensed if it relates to IPR&D or capitalized if it relates to a developed product which is generally considered to be when clinical trials have been completed and regulatory approval obtained. Future royalty payments due on net sales will be recognized in cost of goods sold when net sales are recognized.
Pension accounting	The Company accounts for pension assets and liabilities in accordance with ASC 715, Compensation – Retirement Benefits, which requires the recognition of the funded status of pension plans in the Company’s consolidated balance sheet. The liability in respect to defined benefit pension plans is the projected benefit obligation calculated annually by independent actuaries using the projected unit credit method. The projected benefit obligation as of September 30, 2022 represents the actuarial present value of the estimated future payments required to settle the obligation that is attributable to employee services rendered before that date. Service costs for such pension plans, represented in the net periodic benefit cost, are included in the personnel expenses of the various functions where the employees are engaged. The other components of net benefit cost are included in the consolidated statement of operations separately from the service cost component, in “other income (expenses), net.” Plan assets are recorded at their fair value. Gains or losses arising from plan curtailments or settlements are accounted for at the time they occur. Any net pension asset is limited to the present value of the future economic benefits available to the Company in the form of refunds from the plan or expected reductions in future contributions to the plan. Actuarial gains and losses arising from differences between the actual and the expected return on plan assets are recognized in accumulated other comprehensive income (loss).
Recently issued accounting pronouncements not yet adopted	The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). As such the Company is eligible for exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including reduced reporting and extended transition periods to comply with new or revised accounting standards for public business entities. The Company has elected to avail itself of this exemption and, therefore, will not be subject to the timeline for adopting new or revised accounting standards for public business entities that are not emerging growth companies, and will follow the transition guidance applicable to private companies. In February 2016, the FASB issued ASU No. 2016-02, Leases Topic 842 (“ASU 2016-02”). The guidance in ASU 2016-02 supersedes the lease recognition requirements in ASC 840, Leases. ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases, along with additional qualitative and quantitative disclosures. ASU 2016-02 is effective for fiscal years beginning after December 15, 2021, and for interim periods within fiscal years beginning after December 15, 2022, with early adoption permitted. The Company has continued to account for the open-ended office lease agreement as an operating lease under the guidance prior to ASU 2016-02 through the consolidated statement of operations for the period ended December 31, 2021. In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements, which allows entities to elect a modified retrospective transition method where entities may continue to apply the existing lease guidance during the comparative periods and apply the new lease requirements through a cumulative effect adjustment in the period of adoptions rather than in the earliest period presented.

Business Combination Agreement with Helix and Recapitalization (Tables)

9 Months Ended

Sep. 30, 2022

Reverse Recapitalization [Abstract]

The following table summarizes the elements of the net proceeds from the Business Combination:


	in thousands
Investments held in Trust Account	$	115,051
Less cash to cover redemptions of the Class A Ordinary Shares issued by Helix prior to the Closing Date	(80,842)
Plus PIPE investment	116,000
Less Helix transaction expense	(15,520)
of which accrued expenses	(5,798)
of which deferred IPO underwriting fee	(4,025)
of which other transaction expenses	(5,697)
Available Closing Date Cash	$	134,689

The following table summarizes the number of Ordinary Shares outstanding immediately following the consummation of the Business Combination:


Helix Acquisition Corp. Ordinary Shares prior to the Business Combination			14,805,000
Of which Class A Ordinary Shares (Helix management - IPO private placement shares)			430,000
Of which Class A Ordinary Shares redeemable			11,500,000
Of which Class B Ordinary Shares (Helix management - sponsor promote)			2,875,000
Less redemptions of the Class A Ordinary Shares issued by Helix prior to the Closing Date			(8,080,645)
Plus issuance of Helix Class A Ordinary Shares to PIPE Investors			11,700,000
Plus issuance of Helix Class A Ordinary Shares to BVF Shareholders			18,501,284
Total MoonLake Class A Ordinary Shares Outstanding at Closing			36,925,639
Plus issuance of Helix Class C Ordinary Shares to ML Parties (other than the BVF Shareholders)			15,775,472
Total MoonLake Class A and Class C Ordinary Shares Outstanding at Closing			52,701,111

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2022

Fair Value Disclosures [Abstract]

Schedule of debt securities by level within the fair value hierarchy

The following table presents the Company’s short-term marketable debt securities by level within the fair value hierarchy:


	September 30, 2022
	Level 1		Level 2		Level 3		Total
Eurocommercial Papers	$	32,407,888	$	—	$	—	$	32,407,888
Certificates of Deposit	9,846,900		—		—		9,846,900
Total	$	42,254,788	$	—	$	—	$	42,254,788

Investments (Tables)

9 Months Ended

Sep. 30, 2022

Investments, Debt and Equity Securities [Abstract]

Schedule of investments in short-term marketable debt securities

The fair value and amortized cost of investments in short-term marketable debt securities by major security type as of September 30, 2022 are as follows:


	Amortized cost		Gross unrealized gains		Gross unrealized losses		Fair value
Eurocommercial Papers	$	52,287,157	$	80,994	$	(16,263)	$	52,351,888
Certificates of Deposit	9,834,625		12,275		—		9,846,900
Total	$	62,121,782	$	93,269	$	(16,263)	$	62,198,788
Of which classified within cash and cash equivalents	19,895,762		48,238		—		19,944,000
Of which classified within short-term marketable debt securities	42,226,020		45,031		(16,263)		42,254,788

Schedule of fair value changes of marketable securities

The following table presents the changes in fair values of the Company’s short-term marketable debt securities, classified as level 1 financial assets (in thousands):


Beginning balance, January 1, 2022	$	—
Other comprehensive income before reclassifications	95,815
Amounts reclassified from accumulated other comprehensive income	(18,809)
Net current-period other comprehensive income	77,006
Ending balance, September 30, 2022	$	77,006

Prepaid expenses (Tables)

9 Months Ended

Sep. 30, 2022

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Prepaid expenses


	September 30, 2022		December 31, 2021
Advances on non-clinical research and clinical development services	$	2,208,728	$	547,586
Advances on insurances	2,042,275		23,141
Advances on supply and manufacturing services	83,559		750,622
Other prepayments	144,632		127,747




Total	$	4,479,194	$	1,449,096

Trade and other payables (Tables)

9 Months Ended

Sep. 30, 2022

Trade and other payables, current


	September 30, 2022		December 31, 2021
Supply and manufacturing fees payable	$	523,991	$	183,298
Legal and intellectual property (“IP”) advisory fees payable	155,532		1,233,070
Research and development services	149,161		50,088
Other consulting and advisory services	77,741		71,938


Other payables	149,828		30,896
Total	$	1,056,253	$	1,569,290

Accrued expenses and other current liabilities (Tables)

9 Months Ended

Sep. 30, 2022

Schedule of accrued expenses and other current liabilities


	September 30, 2022		December 31, 2021
Research and development services	$	3,281,331	$	—
Bonuses and related employees compensation expenses	865,882		1,419,137
License fees	520,948		2,055,687
Consultant and other fees	154,806		49,211
Legal fees	77,895		930,354
Tax liabilities	61,608		63,922
Total	$	4,962,470	$	4,518,311

Employee Benefit Plans (Tables)

9 Months Ended

Sep. 30, 2022

Retirement Benefits [Abstract]

Components of Net Periodic Benefit Cost under the Plan


	Three months ended September 30, 2022		Three months ended September 30, 2021		Nine Months Ended September 30, 2022		Nine Months Ended September 30, 2021
Service cost	$	112,222	$	11,423	$	338,173	$	11,423
Interest cost	1,258		—		3,791		—
Expected return on plan assets	(3,862)		—		(11,637)		—

Amortization of unrecognized loss	451		—		1,361		—

Total Net Periodic Benefit Cost	$	110,069	$	11,423	$	331,688	$	11,423

Shareholders’ Equity (Deficit) (Tables)

9 Months Ended

Sep. 30, 2022

Equity [Abstract]

Schedule of Stock Authorized and Issued

As a result of the Business Combination, the Company has retroactively restated the share numbers prior to April 5, 2022 to give effect to the Exchange Ratio.


	Series A Preferred Shares(1)		Common Shares(1)		Common Shares Held In Treasury(2)	Class A Ordinary Shares(3)		Class C Ordinary Shares(3)		Total Number of Shares
	Authorized	Issued	Authorized	Issued	Issued	Authorized	Issued	Authorized	Issued	Authorized	Issued and Outstanding
Balance - December 31, 2021	22,880,908	22,880,908	13,119,092	12,161,331	(1,942,837)	—	—	—	—	36,000,000	33,099,402
Share-based payment under the equity incentive plan ESPP	—	—	—	—	1,177,354	—	—	—	—	—	1,177,354
Balance - March 31, 2022	22,880,908	22,880,908	13,119,092	12,161,331	(765,483)	—	—	—	—	36,000,000	34,276,756
Issuance of Class A Ordinary Shares upon Business Combination	—	—	—	—	—	500,000,000	18,424,355	100,000,000	—	600,000,000	18,424,355
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination	(22,880,908)	(22,880,908)	(13,119,092)	(12,161,331)	765,483	—	18,501,284	—	15,775,472	(36,000,000)	—
Balance - June 30, 2022	—	—	—	—	—	500,000,000	36,925,639	100,000,000	15,775,472	600,000,000	52,701,111
Balance - September 30, 2022	—	—	—	—	—	500,000,000	36,925,639	100,000,000	15,775,472	600,000,000	52,701,111

(1) Fully paid-in registered shares with a par value of CHF 0.10

(2) Registered shares with a par value of CHF 0.10 held in treasury

(3) Fully paid-in registered shares with a par value of $0.0001

Net loss per share (Tables)

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

Schedule of earnings per share, basic and diluted

The following table sets forth the loss per share calculations for the three and nine months ended September 30, 2022 compared to the three and nine months ended September 30, 2021:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Numerator
Net loss attributable to controlling interests shareholders	$	(10,110,452)	$	(6,288,056)	$	(32,865,429)	$	(39,325,510)

Denominator
Total weighted average number of outstanding shares	36,925,639		2,390,587		25,830,560		9,689,627

Net loss per share – basic and diluted	$	(0.27)	$	(2.63)	$	(1.27)	$	(4.06)

Share-based Compensation (Tables)

9 Months Ended

Sep. 30, 2022

Share-Based Payment Arrangement [Abstract]

Share-Based Payment Arrangement, Expensed and Capitalized, Amount

The share-based compensation expense was driven by the following share-based compensation plans and programs:


Compensation Plan	Three months ended September 30, 2022		Three months ended September 30, 2021		Nine Months Ended September 30, 2022		Nine Months Ended September 30, 2021
MoonLake AG Restricted Founder Shares	$	1,210,191	$	1,815,078	$	3,618,226	$	3,065,443
ESPP	1,080,441		39,436		2,829,635		39,436


ESOP	169,907		1,313		370,634		1,313


MoonLake Immunotherapeutics 2022 Equity Incentive Plan	124,621		—		239,760		—
Total share-based compensation expense1	$	2,585,160	$	1,855,827	$	7,058,255	$	3,106,192
Of which: included in R&D expense	161,987		5,461		380,917		5,461
Of which: included in G&A expense	2,423,173		1,850,366		6,677,338		3,100,731

Schedule of Share-Based Payment Award, Non-Option Equity Instruments, Valuation Assumptions

The assumptions used in the valuation of the Restricted Founder Shares awarded are summarized below:


Grant date			4/28/2021
Estimated fair value per share of Restricted Founder Shares on the grant date ($) (1)			49
Estimated fair value of Restricted Founder Shares on the resignation date of one of the co-founders of MoonLake AG ($) (2)			336.39
Purchase price (CHF)			0.10
(1) MoonLake AG estimated the fair value of the Restricted Founder Shares with reference to the market-based transaction with the other Series A Preferred Shares Investors (refer to Note 9 of the audited consolidated financial statements for the year ended December 31, 2021).
(2) MoonLake AG estimated the fair value of the Restricted Founder Shares at co-founder’s resignation date by dividing the Company Enterprise Value ($360,000,000) as defined by the Business Combination Agreement by the Company’s fully diluted shares (1,070,196).

Nonvested Restricted Stock Shares Activity








Grants awarded
Program			Restricted Founder Shares
Awards outstanding at January 1, 2022			4,440,309



Awards vested for the nine months ended September 30, 2022			(2,497,673)
Awards outstanding at September 30, 2022			1,942,634

Schedule of Nonvested Share Activity

The assumptions used in the valuation of the grants awarded under the ESPP for the nine months ended September 30, 2022 are summarized below:


ESPP 2021
Assumptions for the awards issued during the nine months ended September 30, 2022
Grant dates			01/18/2022
Estimated fair value per share of Common Shares on the grant date ($) (1)			336.39
Purchase price (CHF)			0.10
(1) MoonLake AG estimated the fair value of the Common Shares by dividing the Company Enterprise Value ($360,000,000) as defined by the Business Combination Agreement by the Company’s fully diluted shares (1,070,196).

Grants awarded
Program			ESPP
Awards outstanding at January 1, 2022			1,060,561



Awards granted for the nine months ended September 30, 2022			1,177,354
Awards outstanding at September 30, 2022			2,237,915
Awards vested at September 30, 2022			265,241

Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions

The assumptions used in the valuation of the grants awarded under the ESPP for the nine months ended September 30, 2022 are summarized below:


ESPP 2021
Assumptions for the awards issued during the nine months ended September 30, 2022
Grant dates			01/18/2022
Estimated fair value per share of Common Shares on the grant date ($) (1)			336.39
Purchase price (CHF)			0.10
(1) MoonLake AG estimated the fair value of the Common Shares by dividing the Company Enterprise Value ($360,000,000) as defined by the Business Combination Agreement by the Company’s fully diluted shares (1,070,196).

Grants awarded
Program			ESPP
Awards outstanding at January 1, 2022			1,060,561



Awards granted for the nine months ended September 30, 2022			1,177,354
Awards outstanding at September 30, 2022			2,237,915
Awards vested at September 30, 2022			265,241

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions


Weighted average assumptions for the awards issued during the nine months ended September 30, 2022
Grant dates			5/1/2022, 6/22/2022
Estimated fair value of the option on the grant date using Black-Scholes model ($) (1)			172.57
Exercise price (CHF)			27.25
Expected term of the award on the grant date (years) (2)			6
Expected volatility of the share price (3)			0.75
Risk-free interest rate (4)			3%
Expected dividend rate			0
(1) MoonLake AG estimated the fair value of the Common Shares multiplying the MoonLake Immunotherapeutics closing date trading share price on the grant date by the Exchange Ratio. (2) The expected term represents the period that share-based awards are expected to be outstanding. (3) The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company’s industry. (4) The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.


Grant date			4/6/2022
Estimated fair value of the option on the grant date using Black-Scholes model ($)			8.25
Exercise price ($)			12.25
Expected term of the award on the grant date (years)			6
Expected volatility of the share price			75%
Risk-free interest rate			3%
Expected dividend rate			-

Share-Based Payment Arrangement, Option, Activity


Grants awarded
Program			ESOP
Awards outstanding at January 1, 2022			224,033



Awards granted for the nine months ended September 30, 2022			242,737
Awards outstanding at September 30, 2022			466,770
Awards exercisable at September 30, 2022			23,311


Grants awarded
Program	MoonLake Immunotherapeutics 2022 Equity Incentive Plan
Awards outstanding at January 1, 2022		—



Awards granted for the nine months ended September 30, 2022		180,000
Awards outstanding at September 30, 2022		180,000
Awards exercisable at September 30, 2022		—

Business Combination Agreement with Helix and Recapitalization - Narrative (Details)

3 Months Ended

9 Months Ended

Sep. 30, 2022

USD ($)

$ / shares

Apr. 05, 2022

USD ($)

$ / shares

Oct. 04, 2021

USD ($)

$ / shares

Jun. 30, 2022

Sep. 30, 2022

USD ($)

$ / shares

Sep. 30, 2021

USD ($)

^[1]

Apr. 01, 2022

SFr / shares

Dec. 31, 2021

SFr / shares

Schedule Of Reverse Recapitalization [Line Items]

Reverse recapitalization, net | $

$ 134,700,000

$ 134,689,000

Repayments of loan liability | $

$ 15,000,000.0

$ 15,000,000

$ 0

Issuance of Class A ordinary shares upon business combination (in shares)

18,424,355

PIPE Investors

Schedule Of Reverse Recapitalization [Line Items]

Sale of stock (in shares)

11,600,000

Issuance price per share (USD per share) | $ / shares

$ 10.00

Net proceeds from the business combination | $

$ 116,000,000.0

IPO Private Placement Shares

Schedule Of Reverse Recapitalization [Line Items]

Sale of stock (in shares)

100,000

Aggregate fees | $

$ 1,000,000.0

Series A Preferred Shares

Schedule Of Reverse Recapitalization [Line Items]

Preferred stock, par value (CHF per share) | SFr / shares

SFr 0.10

Class V Voting Stock

Schedule Of Reverse Recapitalization [Line Items]

Common shares, shares authorized (in shares)

4,006,736

Common shares, par value (USD per share) | SFr / shares

SFr 0.01

Common stock, votes per share multiplier

Class B Ordinary Shares

Schedule Of Reverse Recapitalization [Line Items]

Common shares, par value (USD per share) | $ / shares

$ 0.0001

Conversion of stock, shares converted

2,875,000

Common stock, conversion ratio (in shares)

Schedule Of Reverse Recapitalization [Line Items]

Common shares, shares authorized (in shares)

500,000,000

Common shares, par value (USD per share) | $ / shares

$ 0.0001

Issuance of Class A ordinary shares upon business combination (in shares)

18,501,284

Sale of stock (in shares)

11,700,000

11,700,000

Class C Ordinary Shares

Schedule Of Reverse Recapitalization [Line Items]

Common shares, shares authorized (in shares)

100,000,000

Common shares, par value (USD per share) | $ / shares

$ 0.0001

Issuance of Helix Class C ordinary shares to ML parties (other than the BVF shareholders) (in shares)

15,775,472

15,775,472

[1]	3 For additional details, refer to Note 3 - Basis of Presentation and Significant Accounting Policies - Restatement of Consolidated Financial Statements as of and for the Three and Nine-months Ended September 30, 2021.

Business Combination Agreement with Helix and Recapitalization - Summary of Net Proceeds (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Apr. 05, 2022
Reverse Recapitalization [Abstract]
Investments held in Trust Account		$ 115,051
Less cash to cover redemptions of the Class A Ordinary Shares issued by Helix prior to the Closing Date		(80,842)
Plus PIPE investment		116,000
Less Helix transaction expense		(15,520)
of which accrued expenses		(5,798)
of which deferred IPO underwriting fee		(4,025)
of which other transaction expenses		(5,697)
Available Closing Date Cash	$ 134,700	$ 134,689

Business Combination Agreement with Helix and Recapitalization - Ordinary Shares Issued (Details) - shares			3 Months Ended
	Apr. 05, 2022	Apr. 04, 2022	Jun. 30, 2022	Sep. 30, 2022
Schedule Of Reverse Recapitalization [Line Items]
Shares outstanding (in shares)	52,701,111
Plus issuance of Helix Class A Ordinary Shares to BVF shareholders (in shares)			18,424,355
Class A Ordinary Shares
Schedule Of Reverse Recapitalization [Line Items]
Shares outstanding (in shares)				36,925,639
Plus issuance of Helix Class A Ordinary Shares to PIPE Investors (in shares)	11,700,000
Plus issuance of Helix Class A Ordinary Shares to BVF shareholders (in shares)	18,501,284
Total MoonLake class A ordinary Shares outstanding at closing (in shares)	36,925,639
Class C Ordinary Shares
Schedule Of Reverse Recapitalization [Line Items]
Shares outstanding (in shares)				15,775,472
Plus issuance of Helix Class A Ordinary Shares to PIPE Investors (in shares)	15,775,472
Issuance of Helix Class C ordinary shares to ML parties (other than the BVF shareholders) (in shares)	15,775,472
Helix Acquisition Corp.
Schedule Of Reverse Recapitalization [Line Items]
Shares outstanding (in shares)		14,805,000
Helix Acquisition Corp. \| Class A Ordinary Shares
Schedule Of Reverse Recapitalization [Line Items]
Less redemptions of class A ordinary shares of the class A ordinary shares issued by Helix prior to the closing date (in shares)		(8,080,645)
Helix Acquisition Corp. \| Common class A, private placement
Schedule Of Reverse Recapitalization [Line Items]
Shares outstanding (in shares)		430,000
Helix Acquisition Corp. \| Common class A, redeemable
Schedule Of Reverse Recapitalization [Line Items]
Shares outstanding (in shares)		11,500,000
Helix Acquisition Corp. \| Class B Ordinary Shares
Schedule Of Reverse Recapitalization [Line Items]
Shares outstanding (in shares)		2,875,000

Basis of Presentation and Significant Accounting Policies (Details)

3 Months Ended

7 Months Ended

9 Months Ended

Apr. 05, 2022

Dec. 13, 2021

Apr. 28, 2021

co-founder

SFr / shares

Sep. 30, 2022

USD ($)

$ / shares

Jun. 30, 2022

Sep. 30, 2021

USD ($)

$ / shares

Sep. 30, 2021

USD ($)

$ / shares

Sep. 30, 2022

USD ($)

$ / shares

Sep. 30, 2021

USD ($)

$ / shares

Exchange ratio

33.638698

Share-based compensation expense | $

52,701,111

$ 2,585,160

$ 1,855,827

$ 7,058,255

$ 3,106,192

Net loss per share - basic (in USD per share) | $ / shares

$ (0.27)

$ (2.63)

$ (1.27)

$ (4.06)

Debt securities, available-for-sale | $

$ 62,198,788

Cash, FDIC Insured Amount | $

100,000

Foreign currency transaction gain (loss) | $

4,361

$ (19,853)

344,914

$ (24,543)

Issuance of Class A ordinary shares upon business combination (in shares)

18,424,355

Of which classified within cash and cash equivalents

Debt securities, available-for-sale | $

19,944,000

$ 19,944,000

Minimum

Property and equipment, useful life

3 years

Maximum

Property and equipment, useful life

5 years

MoonLake AG Restricted Founder Shares

Share-based compensation expense | $

$ 1,210,191

$ 1,815,078

$ 3,618,226

$ 3,065,443

MoonLake AG

Reverse vesting percentage

90.00%

Number of co-founders | co-founder

110,000

Net loss per share - basic (in USD per share) | $ / shares

$ (2.63)

$ (4.06)

Basic EPS before recapitalization exchange ratio adjustment (in USD per share) | $ / shares

(88.48)

(136.52)

MoonLake AG | Previously Reported

Basic EPS before recapitalization exchange ratio adjustment (in USD per share) | $ / shares

(13.55)

(70.56)

Net loss per share, including retroactive adjustments, basic (in USD per share) | $ / shares

$ (0.40)

$ (2.10)

MoonLake AG | MoonLake AG Restricted Founder Shares

Share-based compensation expense | $

99,000

Vesting percentage

4.166%

Vesting period

2 years

$ 1,800,000

$ 3,100,000

Nominal value (CHF per share) | SFr / shares

SFr 0.10

Shares repurchased as a result of terminated contractual relationship with co-founder (in shares)

57,756

11,700,000

Net loss per share - basic (in USD per share) | $ / shares

36,925,639

$ (0.27)

$ 0

^[1]

$ (1.27)

$ 0

^[1]

Issuance of Class A ordinary shares upon business combination (in shares)

18,501,284

Class C Ordinary Shares

15,775,472

Class C Ordinary Shares | MoonLake AG

15,775,472

Class C Ordinary Shares | MoonLake AG | MoonLake AG Restricted Founder Shares

3,700,257

Shares repurchased as a result of terminated contractual relationship with co-founder (in shares)

3,330,231

1,942,837

[1]	1 For additional details, refer to Note 3 - Basis of Presentation and Significant Accounting Policies - Restatement of Consolidated Financial Statements as of and for the Three and Nine-months Ended September 30, 2021.

Risks and Liquidity (Details) - USD ($)

1 Months Ended

3 Months Ended

9 Months Ended

Mar. 31, 2021

Sep. 30, 2022

Jun. 30, 2022

Mar. 31, 2022

Sep. 30, 2021

^[1]

Jun. 30, 2021

Sep. 30, 2022

Sep. 30, 2021

^[1],[2]

Dec. 31, 2021

Risks and Uncertainties [Abstract]

Excess of current assets less current liabilities

$ (351,673)

$ (14,741,648)

$ (17,416,329)

$ (15,880,142)

$ (6,288,056)

$ (32,685,779)

$ (48,038,121)

$ (39,325,510)

82,500,000

Unrestricted cash

41,200,000

Debt securities, available-for-sale

62,198,788

Short-term marketable debt securities

$ 42,254,788

$ 0

[1]	1 For additional details, refer to Note 3 - Basis of Presentation and Significant Accounting Policies - Restatement of Consolidated Financial Statements as of and for the Three and Nine-months Ended September 30, 2021.
[2]	3 For additional details, refer to Note 3 - Basis of Presentation and Significant Accounting Policies - Restatement of Consolidated Financial Statements as of and for the Three and Nine-months Ended September 30, 2021.

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss) [Roll Forward]

Fair Value Measurements (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]
Short-term marketable debt securities	$ 42,254,788	$ 0
Total	42,254,788
Eurocommercial Papers
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]
Short-term marketable debt securities	32,407,888
Certificates of Deposit
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]
Short-term marketable debt securities	9,846,900
Level 1
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]
Total	42,254,788
Level 1 \| Eurocommercial Papers
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]
Short-term marketable debt securities	32,407,888
Level 1 \| Certificates of Deposit
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]
Short-term marketable debt securities	9,846,900
Level 2
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]
Total	0
Level 2 \| Eurocommercial Papers
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]
Short-term marketable debt securities	0
Level 2 \| Certificates of Deposit
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]
Short-term marketable debt securities	0
Level 3
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]
Total	0
Level 3 \| Eurocommercial Papers
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]
Short-term marketable debt securities	0
Level 3 \| Certificates of Deposit
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]
Short-term marketable debt securities	$ 0

Investments (Details)	Sep. 30, 2022 USD ($)
Debt Securities, Available-for-Sale [Line Items]
Amortized cost	$ 62,121,782
Gross unrealized gains	93,269
Gross unrealized losses	(16,263)
Fair value	62,198,788
Of which classified within cash and cash equivalents
Debt Securities, Available-for-Sale [Line Items]
Amortized cost	19,895,762
Gross unrealized gains	48,238
Gross unrealized losses	0
Fair value	19,944,000
Of which classified within short-term marketable debt securities
Debt Securities, Available-for-Sale [Line Items]
Amortized cost	42,226,020
Gross unrealized gains	45,031
Gross unrealized losses	(16,263)
Fair value	42,254,788
Eurocommercial Papers
Debt Securities, Available-for-Sale [Line Items]
Amortized cost	52,287,157
Gross unrealized gains	80,994
Gross unrealized losses	(16,263)
Fair value	52,351,888
Certificates of Deposit
Debt Securities, Available-for-Sale [Line Items]
Amortized cost	9,834,625
Gross unrealized gains	12,275
Gross unrealized losses	0
Fair value	$ 9,846,900

Investments - FV changes (Details) - USD ($)

3 Months Ended

9 Months Ended

Sep. 30, 2022

Sep. 30, 2021

^[1]

Sep. 30, 2022

Sep. 30, 2021

^[1]

Net current-period other comprehensive income

$ 77,006

$ 0

$ 77,006

$ 0

Level 1

Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss) [Roll Forward]

Gross unrealized gain (loss), beginning balance

Other comprehensive income before reclassifications

95,815

Amounts reclassified from accumulated other comprehensive income

(18,809)

Net current-period other comprehensive income

77,006

Gross unrealized gain (loss), ending balance

$ 77,006

[1]	1 For additional details, refer to Note 3 - Basis of Presentation and Significant Accounting Policies - Restatement of Consolidated Financial Statements as of and for the Three and Nine-months Ended September 30, 2021.

Prepaid expenses (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Advances on non-clinical research and clinical development services	$ 2,208,728	$ 547,586
Advances on insurances	2,042,275	23,141
Advances on supply and manufacturing services	83,559	750,622
Other prepayments	144,632	127,747
Total	$ 4,479,194	$ 1,449,096

Trade and other payables (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Supply and manufacturing fees payable	$ 523,991	$ 183,298
Legal and intellectual property (“IP”) advisory fees payable	155,532	1,233,070
Research and development services	149,161	50,088
Other consulting and advisory services	77,741	71,938
Other payables	149,828	30,896
Total	$ 1,056,253	$ 1,569,290

Accrued expenses and other current liabilities (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Research and development services	$ 3,281,331	$ 0
Bonuses and related employees compensation expenses	865,882	1,419,137
License fees	520,948	2,055,687
Consultant and other fees	154,806	49,211
Legal fees	77,895	930,354
Tax liabilities	61,608	63,922
Total	$ 4,962,470	$ 4,518,311

Employee Benefit Plans (Details) - USD ($)	3 Months Ended		9 Months Ended
Employee Benefit Plans (Details) - USD ($)	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Retirement Benefits [Abstract]
Service cost	$ 112,222	$ 11,423	$ 338,173	$ 11,423
Interest cost	1,258	0	3,791	0
Expected return on plan assets	(3,862)	0	(11,637)	0
Amortization of unrecognized loss	451	0	1,361	0
Total Net Periodic Benefit Cost	$ 110,069	$ 11,423	$ 331,688	$ 11,423

Employee Benefit Plans - Narrative (Details)	3 Months Ended		6 Months Ended		9 Months Ended
Employee Benefit Plans - Narrative (Details)	Mar. 31, 2023 USD ($)	Mar. 31, 2023 CHF (SFr)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 CHF (SFr)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 CHF (SFr)
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Contributions made to plan					$ 103,873	SFr 98,806
Forecast
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Contributions made to plan	$ 137,630	SFr 131,415	$ 33,757	SFr 32,609

Shareholders’ Equity (Deficit) - Schedule of Stock Authorized and Issued (Details)		3 Months Ended			9 Months Ended
	Apr. 05, 2022 shares	Jun. 30, 2022 shares	Mar. 31, 2022 shares	Jun. 30, 2021 shares	Sep. 30, 2022 SFr / shares shares	Sep. 30, 2022 $ / shares	Apr. 01, 2022 SFr / shares	Dec. 31, 2021 SFr / shares
Series A Preferred Shares
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		(36,000,000)
Common Shares
Issuance of Class A Ordinary Shares upon Business Combination (in shares)		600,000,000
Issuance of Class A ordinary shares upon business combination (in shares)		18,424,355
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		(36,000,000)
Common Shares Held In Treasury
Share-based payment under the equity incentive plan ESPP (in shares)			1,177,354
Total Number of Shares
Authorized, beginning balance (in shares)		36,000,000	36,000,000		36,000,000
Shares issued, beginning balance (in shares)		34,276,756	33,099,402		33,099,402
Share-based payment under the equity incentive plan ESPP (in shares)			1,177,354
Issuance of Class A Ordinary Shares upon Business Combination (in shares)		600,000,000
Issuance of Class A Ordinary Shares upon Business Combination (in shares)		18,424,355
Authorized, ending balance (in shares)		600,000,000	36,000,000		600,000,000
Shares issued, ending balance (in shares)		52,701,111	34,276,756		52,701,111
Series A Preferred Shares
Series A Preferred Shares
Authorized, beginning balance (in shares)			22,880,908		22,880,908
Issued, beginning balance (in shares)			22,880,908		22,880,908
Total Number of Shares
Series A Preferred Shares, par value (CHF per share) \| SFr / shares							SFr 0.10	SFr 0.10
Class A Ordinary Shares
Common Shares
Issuance of Class A ordinary shares upon business combination (in shares)	18,501,284
Authorized, ending balance (in shares)					500,000,000
Issued, ending balance (in shares)					36,925,639
Total Number of Shares
Issuance of Class A Ordinary Shares upon Business Combination (in shares)	18,501,284
Common stock, par value (CHF/USD per share) \| $ / shares						$ 0.0001
Class C Ordinary Shares
Common Shares
Authorized, ending balance (in shares)					100,000,000
Issued, ending balance (in shares)					15,775,472
Total Number of Shares
Common stock, par value (CHF/USD per share) \| $ / shares						0.0001
Series A Preferred Shares
Series A Preferred Shares
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		(22,880,908)		19,207,697
Common Shares
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		(22,880,908)		19,207,697
Common Shares Held In Treasury
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		(22,880,908)		19,207,697
Total Number of Shares
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		(22,880,908)		19,207,697
Series A Preferred Shares \| Series A Preferred Shares
Series A Preferred Shares
Authorized, beginning balance (in shares)		22,880,908	22,880,908		22,880,908
Issued, beginning balance (in shares)		22,880,908	22,880,908		22,880,908
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		(22,880,908)
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		(22,880,908)
Authorized, ending balance (in shares)		0	22,880,908		0
Issued, ending balance (in shares)		0	22,880,908		0
Common Shares
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		(22,880,908)
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		(22,880,908)
Common Shares Held In Treasury
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		(22,880,908)
Total Number of Shares
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		(22,880,908)
Series A Preferred Shares, par value (CHF per share) \| SFr / shares					SFr 0.10
Common Shares
Series A Preferred Shares
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		(13,119,092)
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		(12,161,331)		(19,207,697)
Common Shares
Authorized, beginning balance (in shares)		13,119,092	13,119,092		13,119,092
Issued, beginning balance (in shares)		12,161,331	12,161,331		12,161,331
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		(13,119,092)
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		(12,161,331)		(19,207,697)
Authorized, ending balance (in shares)		0	13,119,092		0
Issued, ending balance (in shares)		0	12,161,331		0
Common Shares Held In Treasury
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		(12,161,331)		(19,207,697)
Total Number of Shares
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		(12,161,331)		(19,207,697)
Series A Preferred Shares, par value (CHF per share) \| SFr / shares					SFr 0.10
Common Shares \| Class A Ordinary Shares
Series A Preferred Shares
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		18,501,284
Common Shares
Authorized, beginning balance (in shares)		0
Issued, beginning balance (in shares)		0
Issuance of Class A Ordinary Shares upon Business Combination (in shares)		500,000,000
Issuance of Class A ordinary shares upon business combination (in shares)		18,424,355
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		18,501,284
Authorized, ending balance (in shares)		500,000,000	0		500,000,000
Issued, ending balance (in shares)		36,925,639	0		36,925,639
Common Shares Held In Treasury
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		18,501,284
Total Number of Shares
Issuance of Class A Ordinary Shares upon Business Combination (in shares)		500,000,000
Issuance of Class A Ordinary Shares upon Business Combination (in shares)		18,424,355
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		18,501,284
Common stock, par value (CHF/USD per share) \| $ / shares						0.0001
Common Shares \| Class C Ordinary Shares
Series A Preferred Shares
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		15,775,472			15,775,472
Common Shares
Authorized, beginning balance (in shares)		0
Issued, beginning balance (in shares)		0
Issuance of Class A Ordinary Shares upon Business Combination (in shares)		100,000,000
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		15,775,472			15,775,472
Authorized, ending balance (in shares)		100,000,000	0		100,000,000
Issued, ending balance (in shares)		15,775,472	0		15,775,472
Common Shares Held In Treasury
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		15,775,472			15,775,472
Total Number of Shares
Issuance of Class A Ordinary Shares upon Business Combination (in shares)		100,000,000
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		15,775,472			15,775,472
Common stock, par value (CHF/USD per share) \| $ / shares						$ 0.0001
Common Shares Held In Treasury
Series A Preferred Shares
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		765,483
Common Shares
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		765,483
Common Shares Held In Treasury
Held in Treasury, beginning balance (in shares)		(765,483)	(1,942,837)		(1,942,837)
Share-based payment under the equity incentive plan ESPP (in shares)			1,177,354
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		765,483
Held in Treasury, ending balance (in shares)		0	(765,483)		0
Total Number of Shares
Share-based payment under the equity incentive plan ESPP (in shares)			1,177,354
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)		765,483
Common stock, par value (CHF/USD per share) \| SFr / shares					SFr 0.10

Shareholders’ Equity (Deficit) - Narrative (Details)	3 Months Ended		9 Months Ended
Shareholders’ Equity (Deficit) - Narrative (Details)	Jun. 30, 2022 shares	Jun. 30, 2021 shares	Sep. 30, 2022 vote $ / shares shares	Apr. 05, 2022 shares	Mar. 31, 2022 shares	Dec. 31, 2021 shares	Sep. 30, 2021 shares	Mar. 31, 2021 shares	Mar. 10, 2021 shares
Class of Stock [Line Items]
Common Shares, shares outstanding (in shares)				52,701,111
ML parties other than BVF shareholders
Class of Stock [Line Items]
MoonLake AG common shares (in shares)			468,968
Common Shares
Class of Stock [Line Items]
Common Shares, shares issued (in shares)	0		0		12,161,331	12,161,331
Common Shares, shares outstanding (in shares)	0	11,100,770	0		12,161,331	12,161,331	12,127,726	33,638,698	33,638,698
Common shares, shares authorized (in shares)	0		0		13,119,092	13,119,092
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)	(12,161,331)	(19,207,697)
Class A Ordinary Shares
Class of Stock [Line Items]
Common Shares, shares issued (in shares)			36,925,639
Common Shares, shares outstanding (in shares)			36,925,639
Common shares, shares authorized (in shares)			500,000,000
Common shares, par value (USD per share) \| $ / shares			$ 0.0001
Class A Ordinary Shares \| Common Shares
Class of Stock [Line Items]
Common Shares, shares issued (in shares)	36,925,639		36,925,639		0
Common Shares, shares outstanding (in shares)	36,925,639		36,925,639		0
Common shares, shares authorized (in shares)	500,000,000		500,000,000		0
Common shares, par value (USD per share) \| $ / shares			$ 0.0001
Common Shares, votes per share \| vote			1
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)	18,501,284
Class C Ordinary Shares
Class of Stock [Line Items]
Common Shares, shares issued (in shares)			15,775,472
Common Shares, shares outstanding (in shares)			15,775,472
Common shares, shares authorized (in shares)			100,000,000
Common shares, par value (USD per share) \| $ / shares			$ 0.0001
Class C Ordinary Shares \| Common Shares
Class of Stock [Line Items]
Common Shares, shares issued (in shares)	15,775,472		15,775,472		0
Common Shares, shares outstanding (in shares)	15,775,472		15,775,472		0
Common shares, shares authorized (in shares)	100,000,000		100,000,000		0
Common shares, par value (USD per share) \| $ / shares			$ 0.0001
Common Shares, votes per share \| vote			1
Conversion of MoonLake AG shares into Class A Ordinary Shares and Class C Ordinary shares following the Business Combination (in shares)	15,775,472		15,775,472

Net loss per share - Calculation of Net Loss per Share (Details) - USD ($)

3 Months Ended

9 Months Ended

Sep. 30, 2022

Sep. 30, 2021

Sep. 30, 2022

Sep. 30, 2021

Numerator

Net loss attributable to controlling interests shareholders

$ (10,110,452)

$ (6,288,056)

^[1]

$ (32,865,429)

$ (39,325,510)

^[1]

Denominator

Total weighted average number of outstanding shares, basic (in shares)

36,925,639

2,390,587

25,830,560

9,689,627

Total weighted average number of outstanding shares, diluted (in shares)

36,925,639

2,390,587

25,830,560

9,689,627

$ (0.27)

$ (2.63)

$ (1.27)

$ (4.06)

$ (0.27)

$ (2.63)

$ (1.27)

$ (4.06)

[1]	1 For additional details, refer to Note 3 - Basis of Presentation and Significant Accounting Policies - Restatement of Consolidated Financial Statements as of and for the Three and Nine-months Ended September 30, 2021.

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Net loss per share - Narrative (Details) - $ / shares

3 Months Ended

9 Months Ended

Apr. 05, 2022

Sep. 30, 2022

Sep. 30, 2021

Sep. 30, 2022

Sep. 30, 2021

Weighted-average number of shares, basic (in shares)

36,925,639

2,390,587

25,830,560

9,689,627

Weighted-average number of shares, diluted (in shares)

36,925,639

2,390,587

25,830,560

9,689,627

$ (0.27)

$ (2.63)

$ (1.27)

$ (4.06)

$ (0.27)

$ (2.63)

$ (1.27)

$ (4.06)

ML parties other than BVF shareholders

52,701,111

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

MoonLake AG common shares (in shares)

468,968

Pro forma

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Weighted-average number of shares, basic (in shares)

52,701,111

36,116,399

Weighted-average number of shares, diluted (in shares)

52,701,111

36,116,399

$ (0.28)

$ (1.33)

$ (0.28)

$ (1.33)

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

52,701,111

Class C Ordinary Shares

Shares excluded from weighted average number of shares (in shares)

15,775,472

Stock converted (in shares)

15,775,472

Class C Ordinary Shares | Pro forma | ML parties other than BVF shareholders

15,775,472

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Stock forfeited (in shares)

15,775,472

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Weighted-average number of shares, basic (in shares)

^[1]

36,925,639

^[2]

25,830,560

^[2]

Weighted-average number of shares, diluted (in shares)

^[1]

36,925,639

^[2]

25,830,560

^[2]

$ (0.27)

$ 0

^[2]

$ (1.27)

$ 0

^[2]

$ (0.27)

$ 0

^[2]

$ (1.27)

$ 0

^[2]